An organoplatinum compound that possesses antineoplastic activity.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Platinum. A heavy, soft, whitish metal, resembling tin, atomic number 78, atomic weight 195.09, symbol Pt. (From Dorland, 28th ed) It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as "alutiae".
Tumors or cancer of the LUNG.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
A subnormal level of BLOOD PLATELETS.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Organic compounds which contain platinum as an integral part of the molecule.
A statistical means of summarizing information from a series of measurements on one individual. It is frequently used in clinical pharmacology where the AUC from serum levels can be interpreted as the total uptake of whatever has been administered. As a plot of the concentration of a drug against time, after a single dose of medicine, producing a standard shape curve, it is a means of comparing the bioavailability of the same drug made by different companies. (From Winslade, Dictionary of Clinical Research, 1992)
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
Tumors or cancer of the RETINA.
Benign or malignant neoplasms of the FALLOPIAN TUBES. They are uncommon. If they develop, they may be located in the wall or within the lumen as a growth attached to the wall by a stalk.
A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
A malignant tumor arising from the nuclear layer of the retina that is the most common primary tumor of the eye in children. The tumor tends to occur in early childhood or infancy and may be present at birth. The majority are sporadic, but the condition may be transmitted as an autosomal dominant trait. Histologic features include dense cellularity, small round polygonal cells, and areas of calcification and necrosis. An abnormal pupil reflex (leukokoria); NYSTAGMUS, PATHOLOGIC; STRABISMUS; and visual loss represent common clinical characteristics of this condition. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2104)
A decrease in the number of NEUTROPHILS found in the blood.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Disorders of the blood and blood forming tissues.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
Tumors or cancer of the PERITONEUM.
A radiosensitive, malignant neoplasm of the testis, thought to be derived from primordial germ cells of the sexually undifferentiated embryonic gonad. There are three variants: classical (typical), the most common type; anaplastic; and spermatocytic. The classical seminoma is composed of fairly well differentiated sheets or cords of uniform polygonal or round cells (seminoma cells), each cell having abundant clear cytoplasm, distinct cell membranes, a centrally placed round nucleus, and one or more nucleoli. In the female, a grossly and histologically identical neoplasm, known as dysgerminoma, occurs. (Dorland, 27th ed)
Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
Compounds that differ from COUMARINS in having the positions of the ring and ketone oxygens reversed so the keto oxygen is at the 1-position of the molecule.
Immunologically mediated adverse reactions to medicinal substances used legally or illegally.
A malignant neoplasm of the germinal tissue of the GONADS; MEDIASTINUM; or pineal region. Germinomas are uniform in appearance, consisting of large, round cells with vesicular nuclei and clear or finely granular eosinophilic-staining cytoplasm. (Stedman, 265th ed; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1642-3)
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
Derivatives of GLUTAMIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the 2-aminopentanedioic acid structure.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.
Therapeutic act or process that initiates a response to a complete or partial remission level.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Metastases in which the tissue of origin is unknown.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
The forcible expulsion of the contents of the STOMACH through the MOUTH.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Inorganic compounds which contain platinum as the central atom.
Absence of hair from areas where it is normally present.
Proteins involved in the transport of FOLIC ACID and folate derivatives across the CELLULAR MEMBRANE.
Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).
An insect chemosterilant and an antineoplastic agent.
Tumors or cancer of the URINARY TRACT in either the male or the female.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
The action of a drug in promoting or enhancing the effectiveness of another drug.
Transplantation of an individual's own tissue from one site to another site.
Hearing loss in frequencies above 1000 hertz.
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
Abnormally high temperature intentionally induced in living things regionally or whole body. It is most often induced by radiation (heat waves, infra-red), ultrasound, or drugs.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Bcl-2 overexpression results in reciprocal downregulation of Bcl-X(L) and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis. (1/1928)

Testicular germ cell tumours are hypersentive to chemotherapy and cell lines derived from these tumours are chemosensitive in vitro. We have previously shown that these cell lines express undetectable levels of the suppressor of apoptosis Bcl-2 and relatively high levels of the apoptosis inducer Bax (Chresta et al., 1996). To determine whether the absence of Bcl-2 in these cell lines makes them highly susceptible to drug-induced apoptosis, Bcl-2 was expressed ectopically in the 833K testicular germ cell tumour cell line. Stable overexpressing clones were isolated and three clones were studied further. Surprisingly, Bcl-2 overexpressing cells were sensitized to chemotherapy-induced apoptosis compared to the parental and vector control cells. Analysis of potential mechanisms of sensitization revealed there was a reciprocal downregulation of the endogenously expressed Bcl-X(L) in the Bcl-2 overexpressing clones. Downregulation of Bcl-X(L) to the same extent using antisense oligonucleotides enhanced etoposide-induced apoptosis by twofold. Our results indicate that Bcl-2 and Bcl-X(L) have different abilities to protect against chemotherapy-induced apoptosis in testicular germ cell tumours. In contrast to findings in some tumour cell types, Bcl-2 did not act as a gatekeeper to prevent entry of p53 to the nucleus.  (+info)

A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. (2/1928)

Multinuclear platinum compounds have been designed to circumvent the cellular resistance to conventional platinum-based drugs. In an attempt to examine the cellular basis of the preclinical antitumor efficacy of a novel multinuclear platinum compound (BBR 3464) in the treatment of cisplatin-resistant tumors, we have performed a comparative study of cisplatin and BBR 3464 in a human osteosarcoma cell line (U2-OS) and in an in vitro selected cisplatin-resistant subline (U2-OS/Pt). A marked increase of cytotoxic potency of BBR 3464 in comparison with cisplatin in U2-OS cells and a complete lack of cross-resistance in U2-OS/Pt cells were found. A detailed analysis of the cisplatin-resistant phenotype indicated that it was associated with reduced cisplatin accumulation, reduced interstrand cross-link (ICL) formation and DNA platination, microsatellite instability, and reduced expression of the DNA mismatch repair protein PMS2. Despite BBR 3464 charge and molecular size, in U2-OS and U2-OS/Pt cells, BBR 3464 accumulation and DNA-bound platinum were much higher than those observed for cisplatin. In contrast, the frequency of ICLs after exposure to BBR 3464 was very low. The time course of ICL formation after drug removal revealed a low persistence of these types of DNA lesions induced by BBR 3464, in contrast to an increase of DNA lesions induced by cisplatin, suggesting that components of the DNA repair pathway handle the two types of DNA lesions differently. The cellular response of HCT116 mismatch repair-deficient cells was consistent with a lack of influence of mismatch repair status on BBR 3464 cytotoxicity. Because BBR 3464 produces high levels of lesions different from ICLs, likely including intra-strand cross-links and monoadducts, the ability of the triplatinum complex to overcome cisplatin resistance appears to be related to a different mechanism of DNA interaction (formation of different types of drug-induced DNA lesions) as compared with conventional mononuclear complexes rather than the ability to overcome specific cellular alterations.  (+info)

Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer. (3/1928)

PURPOSE: Platinum-based chemotherapy currently represents standard treatment for advanced non-small-cell lung cancer. Gemcitabine is one of the most interesting agents currently in use in advanced non-small-cell lung cancer, and high response rates have been reported when it is administered in combination with cisplatin. The aim of the present study was to evaluate the combination of gemcitabine and carboplatin in a phase I-II study. PATIENTS AND METHODS: Chemotherapy-naive patients with stage IIIB-IV non-small-cell lung cancer received carboplatin at area under the concentration-time curve (AUC) 5 mg/mL/min and gemcitabine at an initial dose of 800 mg/m2, subsequently escalated by 100 mg/m2 per step. Gemcitabine was administered on days 1 and 8 and carboplatin on day 8 of the 28-day cycle. Dose escalation proceeded up to dose-limiting toxicity (DLT), which was defined as grade 4 neutropenia or thrombocytopenia or grade 3 nonhematologic toxicity. RESULTS: Neutropenia was DLT, inasmuch as it occurred in three of five patients receiving gemcitabine 1,200 mg/m2. Nonhematologic toxicities were mild. Gemcitabine 1,100 mg/m2 plus carboplatin AUC 5 was recommended for phase II studies. An objective response was observed in 13 (50%) of 26 patients, including four complete responses (15%) and nine partial responses (35%). Median duration of response was 13 months (range, 3 to 23 months). Median overall survival was 16 months (range, 3 to 26 months). CONCLUSION: The combination of gemcitabine and carboplatin is well tolerated and active. Neutropenia was DLT. The observed activity matches that observable in cisplatin-gemcitabine studies, whereas duration of response and survival are even higher. A phase II trial is under way.  (+info)

Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. (4/1928)

PURPOSE: To evaluate the efficacy of paclitaxel and carboplatin (PC) in small-cell lung cancer (SCLC) patients resistant to cyclophosphamide, doxorubicin, and etoposide (CDE). PATIENTS AND METHODS: We performed a phase II study with PC in SCLC patients who relapsed within 3 months after first-line treatment with CDE. Paclitaxel administration (175 mg/m2 by a 3-hour intravenous infusion) was followed by a 30-minute infusion of carboplatin (area under the curve 7; Chatelut formula) once every 3 weeks for five cycles. Dexamethasone, clemastine, and ranitidine were standard premedication before every cycle. RESULTS: Included were 35 patients (median age, 59 years; 16 with limited disease and 19 with extensive disease; Eastern Cooperative Oncology Group performance status of < or = 1; median time off treatment 6 weeks) who were previously treated with CDE (n = 33), oral etoposide (n = 2), and reinduction CDE (n = 15); only one patient had received three CDE treatments of five cycles. The CDE regimen was followed by local thoracic radiotherapy in seven patients. Hematologic toxicity of grade 3 or 4, for leukopenia was 27% and 6%, for thrombocytopenia 21% and 13%, and for anemia 17% and 0%, respectively, for a total of 132 cycles. Two patients had neutropenic fever; no toxic death occurred. Nonhematologic toxicity was paresthesia CTC grade 3, diarrhea grade 4, and myalgia grade 3 in one patient each. Reversible paresthesia (CTC grade 1 and 2) in toes and fingers was reported in 69% of patients. Thirty-four patients were assessable for response: complete response in two patients, partial response in 23 patients, stable disease in eight patients, and progressive disease in one patient (response rate, 73.5%; 95% confidence interval, 59% to 88%). One patient was found to have atypical carcinoid at pathologic review and was excluded. Median time to progression was 21 weeks (range, 3 to 40 weeks). Median survival was 31 weeks (range, 6 to 112 weeks). One-year survival was 9%. CONCLUSION: Second-line PC in CDE-resistant SCLC patients yields a high response rate and seems non-cross-resistant to CDE. Toxicity was mild in these poor-prognosis patients.  (+info)

Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. (5/1928)

PURPOSE: To determine the maximum-tolerated dose of paclitaxel with carboplatin with and without filgrastim support in patients with metastatic non-small-cell lung cancer (NSCLC) and to investigate the pharmacokinetics of paclitaxel and carboplatin and correlate these with the pharmacodynamic effects. PATIENTS AND METHODS: Thirty-six chemotherapy-naive patients with metastatic NSCLC were entered into this phase I dose-escalation and pharmacokinetic study. Paclitaxel was initially administered as a 24-hour infusion at a fixed dose of 135 mg/m2, and the carboplatin dose was escalated in cohorts of three patients, using Calvert's formula [dose(mg) = area under the concentration time curve (glomerular filtration rate + 25)], to target areas under the concentration time curve (AUCs) of 5, 7, 9, and 11 mg/mL x minute. A measured 24-hour urinary creatinine clearance was substituted for the glomerular filtration rate. Once the maximum-tolerated AUC (MTAUC) of carboplatin was reached, the paclitaxel dose was escalated to 175, 200, and 225 mg/m2. When the paclitaxel dose escalation began, the AUC of carboplatin was reduced to one level below the MTAUC. RESULTS: Myelosuppression was the major dose-limiting toxicity. Thrombocytopenia was observed at a carboplatin AUC of 11 mg/mL x minute after course 2 and thereafter. End-of-infusion plasma paclitaxel concentrations and median duration of time above 0.05 microM were similar in course 1 versus course 2 at the 135 and 175 mg/m2 dose levels. The neutropenia experienced by patients was consistent with that observed in patients who had received paclitaxel alone. Measured carboplatin AUCs were approximately 12% (20% v 3% with course 1 v course 2, respectively) below the desired target, with a standard deviation of 34% at all dose levels. A sigmoid-maximum effect model describing the relationship between relative thrombocytopenia and measured free platinum exposure indicated that patients who received the combination of carboplatin with paclitaxel experienced less severe thrombocytopenia than would be expected from carboplatin alone. Of the 36 patients entered onto the study, one experienced a complete response and 17 had partial responses, for an overall response rate of 50%. The recommended doses of paclitaxel (24-hour infusion) and carboplatin for future phase II studies of this combination are (1) paclitaxel 135 mg/m2 with a carboplatin dose targeted to achieve an AUC of 7 mg/mL x minute without filgrastim support; (2) paclitaxel 135 mg/m2 with a carboplatin dose targeted to achieve an AUC of 9 mg/mL x minute with filgrastim support; and (3) paclitaxel 225 mg/m2 with a carboplatin dose targeted to achieve an AUC of 7 mg/mL x minute with filgrastim support. CONCLUSION: The regimen of paclitaxel and carboplatin is well-tolerated and has promising activity in the treatment of NSCLC. There is no pharmacokinetic interaction between paclitaxel and carboplatin, but there is a pharmacodynamic, platelet-sparing effect on this dose-limiting toxicity of carboplatin.  (+info)

Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. (6/1928)

PURPOSE: An earlier phase II trial of paclitaxel in patients with metastatic nasopharyngeal carcinoma (NPC) demonstrated a response rate of 22%. Hence we proceeded to study the combination of paclitaxel and carboplatin in these patients. PATIENTS AND METHODS: The 21-day regimen was as follows: i.v. paclitaxel 175 mg/m2 over three hours preceded by standard premedications, followed by i.v. carboplatin dosed at AUC of six infused over one hour. Only chemotherapy-naive patients with histological diagnoses of undifferentiated carcinoma of the nasopharynx, systemic metastases and radiologically measurable lesions were eligible. RESULTS: Thirty-two patients were accrued to this study. Twenty patients (62%) had at least two sites of metastasis. The main grade 3-4 toxicity was neutropenia (31%). Nine patients (28%) developed neutropenic sepsis, which caused the demise of one of them. Twenty-four patients (75%) responded to treatment, with one (3%) attaining a complete response. The median time to progression of disease was seven months and the median survival was 12 months. At one year, 52% of the patients were alive. CONCLUSIONS: The combination of paclitaxel and carboplatin is an active regimen in NPC. Its convenience of administration and good tolerability make it an attractive alternative regimen to consider for patients with metastatic disease.  (+info)

Combined treatment modality for intracranial germinomas: results of a multicentre SFOP experience. Societe Francaise d'Oncologie Pediatrique. (7/1928)

Conventional therapy for intracranial germinomas is craniospinal irradiation. In 1990, the Societe Francaise d'Oncologie Pediatrique initiated a study combining chemotherapy (alternating courses of etoposide-carboplatin and etoposide-ifosfamide for a recommended total of four courses) with 40 Gy local irradiation for patients with localized germinomas. Metastatic patients were allocated to receive low-dose craniospinal radiotherapy. Fifty-seven patients were enrolled between 1990 and 1996. Forty-seven had biopsy-proven germinoma. Biopsy was not performed in ten patients (four had diagnostic tumour markers and in six the neurosurgeon felt biopsy was contraindicated). Fifty-one patients had localized disease, and six leptomeningeal dissemination. Seven patients had bifocal tumour. All but one patient received at least four courses of chemotherapy. Toxicity was mainly haematological. Patients with diabetus insipidus (n = 25) commonly developed electrolyte disturbances during chemotherapy. No patient developed tumour progression during chemotherapy. Fifty patients received local radiotherapy with a median dose of 40 Gy to the initial tumour volume. Six metastatic patients, and one patient with localized disease who stopped chemotherapy due to severe toxicity, received craniospinal radiotherapy. The median follow-up for the group was 42 months. Four patients relapsed 9, 10, 38 and 57 months after diagnosis. Three achieved second complete remission following salvage treatment with chemotherapy alone or chemo-radiotherapy. The estimated 3-year survival probability is 98% (CI: 86.6-99.7%) and the estimated 3-year event-free survival is 96.4% (CI: 86.2-99.1%). This study shows that excellent survival rates can be achieved by combining chemotherapy and local radiotherapy in patients with non-metastatic intracranial germinomas.  (+info)

1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. (8/1928)

The majority of men who die from prostate cancer (PC) have hormone-refractory disease. To date, chemotherapeutic agents have had little or no impact on the survival of such patients. To explore a new approach for the treatment of hormone-refractory PC, we examined the combination effects of cis- or carboplatin with vitamin D. 1alpha,25-Dihydroxyvitamin D3 (1alpha,25(OH)2D3) and its synthetic analogue, Ro 25-6760, have an antiproliferative effect on some prostate cancer cell lines. Consequently, the growth-inhibitory effects of the drugs were measured, both singularly and in combination with cis- or carboplatin, on PC cells. Our results show that although each of the drugs alone displayed antiproliferative activity, the growth inhibition of PC cells was further enhanced by the combination of 1alpha,25(OH)2D3 or Ro 25-6760 and either platinum agent. The greatest enhancement of inhibition occurred using smaller concentrations of the platinum compound in combination with higher concentrations of 1alpha,25(OH)2D3. Isobologram analysis revealed that 1alpha,25(OH)2D3 and platinum acted in a synergistic manner to inhibit the growth of PC cells. Our findings suggest that there is potential clinical value in combining 1alpha,25(OH)2D3 with platinum compounds for the treatment of advanced-stage human PC.  (+info)

TY - JOUR. T1 - Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma. T2 - A Japanese Gynecologic Oncology Group study (JGOG2041). AU - Nomura, H.. AU - Aoki, D.. AU - Takahashi, F.. AU - Katsumata, N.. AU - Watanabe, Y.. AU - Konishi, I.. AU - Jobo, T.. AU - Hatae, M.. AU - Hiura, M.. AU - Yaegashi, N.. N1 - Copyright: Copyright 2011 Elsevier B.V., All rights reserved.. PY - 2011/3. Y1 - 2011/3. N2 - Background: The purpose of this study is to assess the efficacy and safety of treatment with taxane plus platinum in combination therapies for advanced or recurrent endometrial carcinoma. Patients and methods: Patients with measurable disease derived from histologically confirmed stage III/IV or recurrent endometrial carcinoma were randomly assigned to receive docetaxel plus cisplatin (DP), docetaxel plus carboplatin (DC), or paclitaxel plus carboplatin (TC) every 3 ...
A comparison of biweekly combination chemotherapy (gemcitabine plus carboplatin) with weekly gemcitabine in elder patients (, 75) with previously untreated advanced non-small cell lung cancer. Primary objective is to determine the objective response rate (CR+PR by RECIST criteria) for biweekly gemcitabine and carboplatin combination chemotherapy versus weekly single gemcitabine as first-line therapy in elder advanced non-small lung cancer patients (, 76 years) who have received no prior treatment for non-small lung cancer. As secondary objectives, adverse event profile, tolerability of biweekly gemcitabine and carboplatin combination chemotherapy, progression-free survival and overall survival will be evaluated in both patients with biweekly gemcitabine and carboplatin combination chemotherapy and weekly single gemcitabine.. The study hypothesis is that biweekly combination chemotherapy of gemcitabine plus carboplatin may improve the efficacy. ...
Platinum-based combinations are the standard second-line treatment for platinum-sensitive ovarian cancer (OC). This randomized phase II study was undertaken in order to compare the combination of carboplatin and pegylated liposomal doxorubicin (LD) with carboplatin and paclitaxel (CP) in this setting. Patients with histologically confirmed recurrent OC, at the time of or more than 6 months after platinum-based chemotherapy, were randomized to six cycles of CP (carboplatin AUC5 + paclitaxel 175 mg/m2, d1q21) or CLD (carboplatin AUC5 + pegylated LD 45 mg/m2, d1q28). A total of 189 eligible patients (CP 96, CLD 93), with a median age of 63 years, median Performance Status (PS) 0 and a median platinum free interval (PFI) of 16.5 months, entered the study. Discontinuation due to toxicity was higher in the CP patients (13.5% versus 3%, P = 0.016). The overall response rate was similar: CP 58% versus CLD 51%, P = 0.309 (Complete Response; CR 34% versus 23%) and there was no statistical difference in time-to
OBJECTIVES: To evaluate the efficacy of combination of navitoclax, carboplatin and paclitaxel in ovarian cancer.. METHODS: 8 ovarian cancer cell lines were treated with either doublet or triplet combinations of navitoclax, carboplatin and paclitaxel. Interactions were assessed by determining a combination index or measuring caspase activity. The effect of the combinations was also evaluated by measuring the inhibition of cells grown as spheroids.. RESULTS: Navitoclax exhibited modest (IC(50)=3-8 μM) single agent potency. Antagonism between carboplatin and paclitaxel was evident in Ovcar-4, Ovcar-8 and Skov-3 cells. Drug combinations including navitoclax with carboplatin and/or paclitaxel showed significantly less antagonism, or even synergy, in several cell lines than carboplatin/paclitaxel alone. Navitoclax enhanced the activation of caspase 3/7 induced by carboplatin and/or paclitaxel in Igrov-1 cells. Combinations of navitoclax, carboplatin and paclitaxel showed more than additive activity ...
This multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of carboplatin/paclitaxel and carboplatin/paclitaxel/bevacizumab with and without pictilisib in particpants with previously untreated advanced or recurrent non-small cell lung cancer (NSCLC). Particpants will be randomized to receive 4 cycles of carboplatin (C)/paclitaxel (P) and either pictilisib or placebo, with (participants with non-squamous NSCLC) or without (participants with squamous NSCLC) bevacizumab (B). Anticipated time on study treatment is until disease progression or intolerable toxicity occurs. Participants in placebo arms with disease progression may cross over to open-label active pictilisib ...
Looking for online definition of Paclitaxel/Carboplatin or what Paclitaxel/Carboplatin stands for? Paclitaxel/Carboplatin is listed in the Worlds largest and most authoritative dictionary database of abbreviations and acronyms
An analysis of the GeparSixto trial in triple-negative breast cancer showed that adding carboplatin to neoadjuvant therapy improved pathologic complete response rate in patients without BRCA1/2 mutation and that response rates were higher overall in those with mutations, without additive effects observed for carboplatin. The analysis was reported by Hahnen et al in JAMA Oncology. GeparSixto showed the addition of neoadjuvant carboplatin to anthracycline, taxane, and bevacizumab (Avastin) increased pathologic complete response rates among all patients.. Study Details The current analysis included 291 patients, of whom 146 received carboplatin. Pathogenic BRCA1 and BRCA2 germline mutations were present in 50 patients (17.2%), including 26 patients who received carboplatin and 24 patients who did not.. Pathologic Complete Response Rate. The pathologic complete response rate was 56.8% in the carboplatin group vs 41.4% in the group that did not receive carboplatin (odds ratio [OR] = 1.87, P = .009). ...
A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC ...
A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC ...
TY - JOUR. T1 - Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy. AU - Xiong, Xiaoxiong. AU - Sui, Meihua. AU - Fan, Weimin. AU - Kraft, Andrew S.. N1 - Funding Information: This work was supported in part by NIH grant and CA92280 (to W.F.).. PY - 2007/7. Y1 - 2007/7. N2 - The combination of carboplatin and paclitaxel is widely used to treat multiple solid tumors including ovarian, lung and breast cancer. Usually these drugs are given simultaneously with little regard to the importance of scheduling to obtain a maximal response. To investigate the importance of sequencing, the human breast Bcap37 and ovarian OV2008 cancer cell lines were exposed to carboplatin and paclitaxel in three different sequences: (1) pretreatment with paclitaxel followed by carboplatin, (2) pretreatment of carboplatin followed by paclitaxel and (3) simultaneous treatment with these two agents. The combination of carboplatin and paclitaxel resulted in antagonistic ...
View more ,Background: Trimodality therapy (TMT) with neoadjuvant chemoradiotherapy (nCRT) using concurrent carboplatin plus paclitaxel (CP) followed by surgery is the standard of care for locoregional esophageal or gastroesophageal junction (GEJ) cancers. Alternatively, nCRT with cisplatin plus fluorouracil (CF) can be used. Definitive chemoradiotherapy (dCRT) with CP or CF can be used if surgery is not planned. In the absence of comparative trials, we aimed to evaluate outcomes of CP and CF in the settings of TMT and dCRT. Methods: A single-site, retrospective cohort study was conducted at the Princess Margaret Cancer Centre to identify all patients who received CRT for locoregional esophageal or GEJ cancer. Overall survival (OS) and disease-free survival (DFS) were assessed using the Kaplan-Meier method and multivariable Cox regression model. The inverse probability treatment weighting (IPTW) method was used for sensitivity analysis. Results: Between 2011 and 2015, 93 patients with esophageal ...
To report the results of combined chemoradiation (CCRT) with cisplatin versus carboplatin in locally advanced cervical carcinoma. From 2009 to 2013, 255 patients with stage IIB-IVA cervical carcinoma, according to FIGO staging were prospectively assigned to be treated with pelvic radiotherapy followed by brachytherapy given concurrently with cisplatin or carboplatin in the treatment of locally advanced cervical cancer. Treatment outcomes and toxicitiy were evaluated. Two-hundred and thirteen patients could be evaluated. At a median follow-up time of 43 months (6-69 months), the 3-year local control, disease-free survival, metastasis-free survival and overall survival rates were 93, 80.8, 85.0 and 87.3 %, respectively. No statistical difference in terms of local control, disease-free survival, metastasis-free survival and overall survival rates between cisplatin and carboplatin treatments was observed in this study. Eighty-six percents of the patients in the carboplatin group could receive more than 4
The combination of carboplatin-paclitaxel is a global standard following recent consensus recommendations [20, 4]. Although this treatment is highly effective, most patients recur. The majority are platinum-sensitive at first relapse, thus, candidates for re-treatment with platinum. Indeed, these patients will be generally re-treated with a platinum-taxane combination, especially in the light of recent trials showing advantage over platinum monotherapy [9]. However, the cumulative neurotoxicity of both drugs, as well as the increased risk of neurotoxicity for patients in relapse and the further experience of alopecia, are essential considerations when selecting second-line therapy [21]. As treatment at relapse is rarely curative, toxicity, tolerance, ease of administration and QoL should be interrelated to efficacy and survival prolongation when novel platinum-based combinations are evaluated for patients with platinum-sensitive OC.. This study was originally designed in 1999, in an era when ...
Materials and methods The overall number of patients and carboplatin courses, sex, age, diagnosis and percentage overdose were extracted from the Farmis database on cytostatics management, from January 2011 to September 2013. Overdoses were designated: carboplatin dosing ,900 mg for a target AUC = 6; carboplatin dosing ,750 mg for a target AUC = 5; carboplatin dosing ,600 mg for a target AUC = 4. In the event of overdosing (Common Terminology Criteria for Adverse Events (CTCAE) criteria), blood tests were sought before the next round of treatment and the need to delay the chemotherapy treatment were evaluated.. ...
Patients and Methods Six hundred sixty-seven patients with stage I to IV CCC of the ovary were randomly assigned to receive irinotecan 60 mg/m2 on days 1, 8, and 15 plus cisplatin 60 mg/m2 on day 1 (CPT-P group) every 4 weeks for six cycles or paclitaxel 175 mg/m2 plus carboplatin area under the curve 6.0 mg/mL/min on day 1 every 3 weeks for six cycles (TC group). The primary end point was progression-free survival. Secondary end points were overall survival, overall response rate, and adverse events ...
The UK Medical Research Council conducted this trial of carboplatin chemotherapy in advanced seminoma to compare single agent carboplatin with a standard combination of etoposide with cisplatin. The use of single agent carboplatin was expected to be associated with reduced toxicity. A total of 130 patients with advanced seminoma were randomly assigned to treatment with either single agent carboplatin (C) at a dose of 400 mg/m(2)to be corrected for glomerular filtration rate outside the range 81-120 ml min(-1)and to be administered on day 1 of a 21 day cycle to a total of 4 cycles or to etoposide + platinum (EP). The trial was designed as an equivalence study aiming to exclude a reduction in the 3-year progression-free survival in patients allocated to carboplatin of between 10 and 15%, requiring initially a target accrual of 250 patients (90% power significance level 5% (one-sided)). The trial closed after 130 patients had been randomized following recommendation by an independent data ...
TY - JOUR. T1 - Paclitaxel plus carboplatin. T2 - An effective combination chemotherapy for advanced non-small-cell lung cancer or just another elvis sighting?. AU - Johnson, D. H.. AU - Einhorn, L. H.. PY - 1995/1/1. Y1 - 1995/1/1. UR - http://www.scopus.com/inward/record.url?scp=0029130242&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0029130242&partnerID=8YFLogxK. U2 - 10.1200/JCO.1995.13.8.1840. DO - 10.1200/JCO.1995.13.8.1840. M3 - Editorial. C2 - 7636526. AN - SCOPUS:0029130242. VL - 13. SP - 1840. EP - 1842. JO - Journal of Clinical Oncology. JF - Journal of Clinical Oncology. SN - 0732-183X. IS - 8. ER - ...
Chemotherapies are associated with significant inter-individual variability in therapeutic effect and adverse drug reactions. In lung cancer the use of gemcitabine and carboplatin induces grade 3-4 myelosuppression in about ¼ of the patients while an equal fraction of patients are basically unaffected in terms of myelosuppressive side effects. We therefore set out to try to identify genetic markers for gemcitabine / carboplatin induced myelosuppression. We selected 32 patients that suffered extremely high neutropenia and thrombocytopenia (grade 3 or 4 after first chemotherapy cycle) or were virtually unaffected (grade 0-1 after the first chemotherapy cycle) by the chemotherapy out of 243 lung cancer patients treated with gemcitabine / carboplatin. These patients were exome sequenced and their genetic differences compared using six different bioinformatic strategies; whole exome non-synonymous SNV association analysis, deviation from Hardy-Weinberg equilibrium, analysis of genes selected by a ...
LOS ANGELES--Interim analysis of a major German-Austrian trial comparing cisplatin (Platinol)/paclitaxel (Taxol) with carboplatin (Paraplatin)/paclitaxel as first-line treatment in ovarian cancer found significantly less toxicity with carboplatin/paclitaxel, with no apparent loss of efficacy. 1
We have previously reported on bilateral intra-arterial (IA) chemosurgery for bilateral retinoblastoma, or tandem therapy.1 While this allows both eyes to be treated during the same IA session, it also exposes the patient to twice the dose of chemotherapy (typically melphalan and topotecan). Even at the doses used for IA, the systemic levels of melphalan can be dose-limiting (melphalan may induce neutropenia at doses higher than 0.4 mg/kg). To obviate the need for melphalan dose restriction during tandem therapy, we report on the use of single agent carboplatin to the fellow eye. ...
TY - JOUR. T1 - A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma. T2 - A Gynecologic Oncology Group Study. AU - Mannel, Robert S.. AU - Brady, Mark F.. AU - Kohn, Elise C.. AU - Hanjani, Parviz. AU - Hiura, Masamichi. AU - Lee, Roger. AU - DeGeest, Koen. AU - Cohn, David E.. AU - Monk, Bradley J.. AU - Michael, Helen. PY - 2011/7/1. Y1 - 2011/7/1. N2 - Objective: To compare the recurrence-free interval (RFI) and safety profile in patients with completely resected high-risk early-stage ovarian cancer treated with intravenous (IV) carboplatin and paclitaxel with or without maintenance low-dose paclitaxel for 24 weeks. Methods: Eligibility was limited to patients with stage IA/B (grade 3 or clear cell), all IC or II epithelial ovarian cancer. All patients were to receive carboplatin AUC 6 and paclitaxel 175 mg/m2 q3 weeks × 3 courses with random assignment ...
TY - JOUR. T1 - Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. AU - Lara, Primo N. AU - Douillard, Jean Yves. AU - Nakagawa, Kazuhiko. AU - Von Pawel, Joachim. AU - McKeage, Mark J.. AU - Albert, Istvan. AU - Losonczy, Gyor̈gy. AU - Reck, Martin. AU - Heo, Dae Seog. AU - Fan, Xiaolin. AU - Fandi, Abderrahim. AU - Scagliotti, Giorgio. PY - 2011/8/1. Y1 - 2011/8/1. N2 - Purpose: This phase III trial was conducted to test whether the novel vascular disrupting agent ASA404 (vadimezan), when combined with first-line platinum-based chemotherapy, improves survival in patients with advanced non-small-cell lung cancer (NSCLC) versus chemotherapy alone. Patients and Methods: Patients with advanced stage IIIB or IV NSCLC, stratified by sex and tumor histology, were randomly assigned 1:1 to paclitaxel (200 mg/m2) and carboplatin (area under the curve, 6.0) with or without ...
TY - JOUR. T1 - Comparison of concurrent use of thoracic radiation with either carboplatin-paclitaxel or cisplatin-etoposide for patients with stage III non-small-cell lung cancer. T2 - A systematic review. AU - Steuer, Conor E.. AU - Behera, Madhusmita. AU - Ernani, Vinicius. AU - Higgins, Kristin A.. AU - Saba, Nabil F.. AU - Shin, Dong M.. AU - Pakkala, Suchita. AU - Pillai, Rathi N.. AU - Owonikoko, Taofeek K.. AU - Curran, Walter J.. AU - Belani, Chandra P.. AU - Khuri, Fadlo R.. AU - Ramalingam, Suresh S.. PY - 2017/8. Y1 - 2017/8. N2 - IMPORTANCE: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide. There are no prospective comparisons of these 2 regimens in this setting. OBJECTIVE: To conduct a systematic review of published trials to compare outcomes and toxic effects between cisplatin-etoposide and carboplatin-paclitaxel in ...
Fingerprint Dive into the research topics of Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study. Together they form a unique fingerprint. ...
Background AMG 386, an investigational peptibody, blocks the interaction of angiopoietin-1 and -2 with the Tie2 receptor, thereby inhibiting tumor angiogenesis. We evaluated the tolerability of AMG 386 plus paclitaxel and carboplatin in ovarian cancer patients who had primary or interval debulking surgery (PDS or IDS, respectively).. Methods Women (≥ 18 yrs, GOG ≤ 1) with high-risk stage I (grade 3 or aneuploid grade 1 or 2) or II-IV ovarian cancer received 6 cycles of the combination AMG 386 (15 mg/kg IV QW) plus paclitaxel (175 mg/m2 IV Q3W) and carboplatin (AUC 6 IV Q3W) followed by AMG 386 maintenance monotherapy up to 18 months. Patients had PDS; patients with disease stage IIIC or IV had the option of planned IDS. AMG 386 dosing was withheld for > 4 weeks after PDS or before IDS. The primary endpoint was the incidence of dose-limiting toxicities (DLTs), which determined cohort expansion to n = 25; secondary endpoints included the patient incidence of adverse events (AEs), the incidence ...
The use of weekly chemotherapy for the treatment of patients with advanced-stage serous-type epithelial Tubo-ovarian cancer (ETOC), and primary peritoneal serous carcinoma (PPSC) is acceptable as the front-line postoperative chemotherapy after primary cytoreductive surgery (PCS). The main component of dose-dense chemotherapy is weekly paclitaxel (80 mg/m2), but it would be interesting to know what is the difference between combination of triweekly cisplatin (20 mg/m2) or triweekly carboplatin (carboplatin area under the curve 5-7 mg/mL per min [AUC 5-7]) in the dose-dense paclitaxel regimen. Therefore, we compared the outcomes of women with Gynecology and Obstetrics (FIGO) stage IIIC ETOC and PPSC treated with PCS and a subsequent combination of dose-dense weekly paclitaxel and triweekly cisplatin (paclitaxel–cisplatin) or triweekly carboplatin using AUC 5 (paclitaxel–carboplatin). Between January 2010 and December 2016, 40 women with International Federation of Gynecology and Obstetrics
Fingerprint Dive into the research topics of Dose-dense paclitaxel/carboplatin as neo-adjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer: a prospective phase II study. Together they form a unique fingerprint. ...
Rare Cancer News & Clinical Trials » Trial - Sarcoma » Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or ...
Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced continued encouraging results in an ongoing Massachusetts General Hospital Cancer Center and Dana-Farber/Harvard Cancer Center (DF/HCC) Phase 2 trial of NOV-002 in combination with carboplatin in platinum-resistant ovarian cancer patients. Fifteen patients have now been enrolled and, to date, 60% (9) have had slower than expected disease progression. NOV-002 was well-tolerated, further extending the excellent safety profile NOV-002 has demonstrated in previous studies. Detailed results of this trial will be presented as a poster at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO) taking place May 30 - June 3 in Chicago, Illinois.. I am encouraged by these results in platinum-resistant ovarian cancer, with NOV-002 (in combination with carboplatin) apparently slowing disease progression in over half of the ...
Background: This study evaluated safety, pharmacokinetics, and clinical activity of intravenous and oral rucaparib, a poly (ADP-ribose) polymerase inhibitor, combined with chemotherapy in patients with advanced solid tumours. Methods: Initially, patients received escalating doses of intravenous rucaparib combined with carboplatin, carboplatin/paclitaxel, cisplatin/pemetrexed, or epirubicin/cyclophosphamide. Subsequently, the study was amended to focus on oral rucaparib (once daily, days 1-14) combined with carboplatin (day 1) in 21-day cycles. Doselimiting toxicities (DLTs) were assessed in cycle 1 and safety in all cycles. Results: Eighty-five patients were enrolled (22 breast, 15 ovarian/peritoneal, 48 other primary cancers), with a median of three prior therapies (range, 1-7). Neutropenia (27.1%) and thrombocytopenia (18.8%) were the most common grade ≥3 toxicities across combinations and were DLTs with the oral rucaparib/carboplatin combination. Maximum tolerated dose for the combination was 240
This study is investigating whether the addition of another drug, Amifostine, can reduce the side effects of current combination treatment (radiation and
Marty - Youre right...on the time difference. Like you, the bigger doses during the nine weeks took anywhere from 6 - 8+ hours with all of the additional solutions and only one chemo at a time.. The Carboplatin usually only took an hour or so. The day I had chemo, Id also go down and do the rads after.. Well, Id get the Amifostine injection in the tummy first, then rads. Amifostine injection and rads every day for seven weeks....uggg.. Pat - about the only side effect I did have during the Cisplatin, Taxotere and 5FU was I lost my hair (all hair) around week 3 - 4, then it starting growing back within a few weeks.. When I started the Carboplatin, the hair was already back, though really fine an just like first hair...LOL, it was kind of humorous.. Well, thinking back, I did also lose all of my toe nails (a little weird) my finger nails became really brittle also. I also initially had hiccups frequently, and my potassium dropped, had to have extra for 10 days once.. JG ...
A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (anti-pd-l1 antibody) in combination with gemcitabine/carboplatin versus gemcitabine/carboplatin alone in patients with untreated locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-based therapy
To determine the maximum-tolerated dose and the recommended dose of radiation and carboplatin and pemetrexed in locally advanced non-small cell lung cancer.
TY - JOUR. T1 - Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer. T2 - a phase 3, open-label, randomised controlled trial. AU - Katsumata, Noriyuki. AU - Yasuda, Makoto. AU - Takahashi, Fumiaki. AU - Isonishi, Seiji. AU - Jobo, Toshiko. AU - Aoki, Daisuke. AU - Tsuda, Hiroshi. AU - Sugiyama, Toru. AU - Kodama, Shoji. AU - Kimura, Eizo. AU - Ochiai, Kazunori. AU - Noda, Kiichiro. N1 - Funding Information: SI and DA have received honoraria from Bristol-Myers Squibb. DA and HT have received grant support from Bristol-Myers Squibb. All other authors declare that they have no conflicts of interest. Funding Information: This study was funded by an unrestricted grant from Bristol-Myers Squibb. We thank the women who participated in this trial and Akihiro Yanagisawa, Kei Matsubara for assisting protocol design and review, Keiichi Fujiwara for internal auditing, and Robert F Ozols for protocol design and manuscript review. PY - 2009. Y1 - ...
TY - JOUR. T1 - Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer. T2 - Preliminary results comparing sequential phase II trials. AU - DeVore, R. F.. AU - Jagasia, M.. AU - Johnson, D. H.. PY - 1997/10/22. Y1 - 1997/10/22. N2 - Our group previously described the activity of carboplatin plus paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) (given as a 24-hour infusion) in 51 patients with advanced non-small cell lung cancer. To facilitate outpatient administration, the regimen was modified to infuse paclitaxel over 1 hour. Between February 1995 and August 1996, 63 patients with advanced non-small cell lung cancer were accrued by the Vanderbilt Cancer Center and its affiliate network. The first four patients received paclitaxel 175 mg/ml2; all subsequent patients received paclitaxel 200 mg/m2. The carboplatin dose was determined using the Calvert formula, with a target area under the concentration-time curve of 6. ...
TY - JOUR. T1 - Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. AU - Lemma, Girum L.. AU - Lee, Ju Whei. AU - Aisner, Seena C.. AU - Langer, Corey J.. AU - Tester, William J.. AU - Johnson, David H.. AU - Loehrer, Patrick J.. PY - 2011/5/20. Y1 - 2011/5/20. N2 - Purpose: The purpose of this study was to evaluate the impact of carboplatin and paclitaxel in patients with advanced previously untreated thymoma and thymic carcinoma. Patients and Methods We conducted a prospective multicenter study in patients with unresectable thymoma (n = 21) or thymic carcinoma (n = 23). Patients were treated with carboplatin (area under the curve, 6) plus paclitaxel (225 mg/m2) every 3 weeks for a maximum of six cycles. The primary end point of this trial was to evaluate the objective response rate. Results: From February 2001 through January 2008, 46 patients were enrolled. Thirteen patients had grade 4 or greater toxicity, mostly neutropenia. Using RECIST (Response ...
Japans largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
Scientists at Dana-Farber Cancer Institute have shown that experimental diabetes drugs can make cancer cells more vulnerable to traditional chemotherapy agents, and they say such combinations should be explored to potentially improve outcomes for cancer patients.. Reporting in the Proceedings of the National Academy of Sciences, investigators demonstrated in cancer cell lines and animal models that the research compounds - similar to common anti-diabetic agents known as thiazolidinediones (TZDs) - sensitized lung tumor cells to carboplatin chemotherapy. Tumors in rodents treated with the combination of carboplatin and one of the experimental compounds, SR1664, weighed less than those in animals treated with carboplatin alone.. The research also showed that the combination sensitized triple-negative breast cancer cells in the laboratory, causing them to self-destruct. However, not all types of cancer cells appear to be made vulnerable to chemotherapy combined with the experimental compounds, the ...
The addition of bevacizumab (Avastin) to gemcitabine and carboplatin, followed by bevacizumab until disease progression, resulted in significantly improved progression-free survival compared to gemcitabine and carboplatin plus placebo among women with platinum-sensitive recurrent ovarian, primary periotoneal, or fallopian tube cancer. Results from the phase III OCEANS (Ovarian Cancer Study Comparing the Efficacy and Safety of Chemotherapy and Anti-Angiogenic Therapy in Platinum-Sensitive Recurrent Disease) trial were published in the Journal of Clinical Oncology.1 The study was sponsored by Genentech, which manufactures bevacizumab.. Analysis of Progression-free Survival. Both treatment groups consisted of 242 patients with histologically confirmed disease progression and ≥ 6 months after completion of front-line platinum-based chemotherapy. At the time of the final [progression-free survival] analysis (338 events), the median follow-up was 24 months, the authors reported. The median ...
Jonathan Goldman, MD explains IMFINZI is the first immunotherapy to show both significant survival benefit and improved, durable responses in extensive-stage small cell lung cancer._______In the Phase III CASPIAN trial IMFINZI at a fixed, convenient dose improved survival with either a cisplatin or carboplatin chemotherapy backboneAstraZeneca today presented detailed results from the Phase III CASPIAN trial, showing IMFINZI® (durvalumab) significantly improved overall survival (OS) in patients with previously-untreated extensive-stage small cell lung cancer (SCLC). IMFINZI in combination with four cycles of standard-of-care (SoC) chemotherapy (etoposide with either cisplatin or carboplatin) demonstrated a statistically-significant and clinically-meaningful improvement in OS vs. SoC chemotherapy consisting of up to six cycles of chemotherapy and optional prophylactic cranial irradiation (PCI). The risk of death was reduced by 27% (equal to a hazard ratio of 0.73), with median OS of 13.0 months for
The meta-analysis of data from 53 studies including 6,885 patients with stage III-IV epithelial ovarian cancer who underwent cytoreductive surgery followed by cisplatin or carboplatin-based chemotherapy showed that percent maximal cytoreduction was an independent prognostic variable for survival (P ,0.001) [2]. Each 10% increase in maximal cytoreduction was associated with a 5.5% increase in median survival. It is noteworthy that median survival time was 23.0 months for patients who had maximal cytoreductive surgery rate of 25% or less compared to 36.8 months for those in which maximal cytoreductive surgery was achieved in more than 75% of cases. The present study confirms that optimal surgical cytoreduction is the most important prognostic factor for advanced epithelial ovarian cancer [2-5, 7, 10, 17]. All attempts should be made to achieve complete cytoreduction, but when this result is not achievable, the surgical goal should be al least a residual disease , 1 cm [7]. Optimal cytoreduction ...
This randomized phase II trial studies paclitaxel and carboplatin to see how well they work compared with bleomycin sulfate, etoposide phosphate, and cisplatin in treating patients with sex cord-ovarian stromal tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or has returned (recurrent). Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective in treating sex cord-ovarian stromal tumors. ...
Amifostine protects normal tissue from the cytotoxic damage induced by radiation and chemotherapy. in this study. 39 consecutive newly diagnosed children with osteosarcoma were assessed; 20 received amifostine and 19 did not. the chemotherapy regimen included an induction phase of three cycles of cisplatin (100 mg/m(2)), carboplatin (500 mg/m(2)), and doxorubicin (60 mg/m(2)), followed by surgery. Alternating cycles of cisplatin/ifosfamide (9 mg/m(2)), ifosfamide/doxorubicin. carboplatin/doxorubicin, and ifosfamide/carboplatin were administered every 3 weeks to complete 26 weeks of treatment. Amifostine was administered 15 minutes before the infusions of cisplatin and carboplatin in a total of 193 infusions. Side effects during infusions and renal, hearing, and bone marrow toxicities were evaluated and compared between the two groups. Hypotension was observed in 28 (14.5%) infusions. No patient required discontinuation of therapy. Fewer than two episodes of vomiting occurred in 130 (71%) ...
Clinical trial for Recurrent Thymic Carcinoma | Locally Advanced Thymic Carcinoma | Unresectable Thymic Carcinoma | Metastatic Thymic Carcinoma , Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced Recurrent or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
Package insert & quality information about side effects from cancer-pharmacist experts on Non-Small Cell Lung Cancer (NSCLC) | Carboplatin + Abraxane
Forty-nine trials involving 8763 women were included. The data were combined to calculate hazard ratios (HR) for survival on an intention-to-treat basis. For single non-platinum versus platinum combination chemotherapy the overall HR for survival was 0.93, 95% confidence interval (CI) 0.83 to1.05 favouring platinum-based combination chemotherapy. For non-platinum regimens compared with the same regimen plus cisplatin the survival HR was 0.88, 95% CI 0.79 to 0.98 in favour of adding platinum to drug regimens. Single platinum compared with platinum combination gave a HR of 0.91, 95% CI 0.79 to 1.05 favouring combination chemotherapy. Cisplatin versus carboplatin gave a HR of 1.02, 95% CI 0.93 to 1.12. Sub-group analyses for age, stage, grade, histology, resection, bulk of residual tumour and performance status were undertaken for cisplatin versus carboplatin only. No difference in effect was found. ...
Squamous cell carcinomas of the oral mucosa are known to be very aggressive and often very frustrating in their therapy. Does this combination of carboplatin and piroxicam coming from human medicine offer better therapeutic results than the current therapies? At least the preliminary results seems to be promising!
Here we provide evidence to get an inherent function for Arpc1b, an element from the Arp2/3 complex, in regulation of mitosis and demonstrate that its depletion inhibits Aurora A activation on the centrosome and impairs the power of mammalian cells to enter mitosis. (Marumoto et al., 2005). Association of Aurora A with centrosomes, spindle poles, aster microtubules, as well as the midbody facilitates its function in regulating centrosome maturation, duplication, Carboplatin kinase activity assay and cell routine progression, which are often affected and dysregulated in the lack of Aurora A (Katayama et al., 2003). Lack of Aurora A in embryonic mice is normally lethal because of flaws in mitotic spindle set up and misaligned and lagging chromosomes (Sasai et al., 2008). On the other hand, Aurora A up-regulation promotes centrosome amplification, aneuploidy, and cancers, and Aurora kinase appearance is normally often elevated in lots of cancer tumor types (Katayama et al., 2003). The paramount ...
TY - JOUR. T1 - Novel separation method for highly sensitive speciation of cancerostatic platinum compounds by HPLC-ICP-MS. AU - Hann, S.. AU - Stefánka, Zs. AU - Lenz, K.. AU - Stingeder, G.. PY - 2005/1/1. Y1 - 2005/1/1. N2 - A high-performance liquid chromatography-inductively coupled plasma mass spectrometry (HPLC ICP-MS) method is presented for analysis of cisplatin, monoaquacisplatin, diaquacisplatin, carboplatin, and oxaliplatin in biological and environmental samples. Chromatographic separation was achieved on pentafluorophenylpropyl-functionalized silica gel. For cisplatin, carboplatin, and oxaliplatin limits of detection of 0.09, 0.10, and 0.15 μg L -1, respectively, were calculated at m/z 194, using aqueous standard solutions. (3 μL injection volume). The method was utilized for model experiments studying the stability of carboplatin and oxaliplatin at different chloride concentrations simulating wastewater and surface water conditions. It was found that a high fraction of ...
Hi Terry,. Im sorry to hear about your daughter. I did carbo/taxol every three weeks for three rounds. I did not find that it was so unbearable, I seemed to tolerate it fairly well. What are your daughters complaints with the side effects? Nausea/vomiting may mean she needs to try a different anti-nausea med. There are also appetite stimulants that can be prescribed. If the bone/joint pain was an issue try L-Glutamine poweder three times a day, movement/walking/stretching, and make sure that her doctor is aware of her discomfort so that he can authorize appropriate pain relief for her.. Carbo/taxol, as far as I know, does not cause damage to hearing or sight. Cisplatin is known to cause hearing loss, which is similar to carboplatin, but carboplatin is much less likely to cause hearing loss. Carboplatin also is less likely to damage kidney than cisplatin though I beleive it causes more myelosuppression. I hope she is feeling better soon. I know she is strong and can make it through the treatment. ...
There were no toxic deaths in either the infusional or fractionated ICE studies. The toxicities in the infusional studyr are not fully described but the same group also published a study of ICE salvage in 163 patients with non-Hodgkin lymphoma.r In this group, thrombocytopenia was the dose limiting toxicity with grade 3/4 thrombocytopenia occurring in 29% of cycles given and 30% of patients requiring platelet transfusion. 13% of cycles were complicated by grade 4 neutropenia requiring hospital admission. The neutrophil nadir occurred 7 to 9 days after the beginning of the cycle. Anaemia was a common occurrence with 98 patients requiring red cell transfusions. Non-haematological toxicities were uncommon and included gross haematuria in 4 of 381 cycles, one case of reversible nephrotoxicity, two cardiac toxicities (congestive cardiac failure & supraventricular tachycardia) and 5 cases of neurological toxicity (1 peripheral neuropathy and 4 confusion due to ifosfamide-induced encephalopathy). The ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations.. This Tecentriq regimen has demonstrated a significant survival benefit in the initial treatment of metastatic non-squamous non-small cell lung cancer, said Sandra Horning, MD, Roches Chief Medical Officer and Head of Global Product Development. Todays approval supports our combination approach for Tecentriq in lung cancer and our vision to develop medicines that improve outcomes for patients with this complex disease.. This approval is based on results from the Phase III IMpower150 study, which showed that Tecentriq in combination with Avastin and chemotherapy helped people live significantly longer, compared to ...
article{3574ec13-af1d-46ee-a05a-eaab584bbe9e, abstract = {Background: The purpose was to investigate adjuvant marrow-supportive high-dose chemotherapy compared with an equitoxicity-tailored comparator arm. Patients and methods: Five hundred and twenty-five women below the age of 60 years with operated high-risk primary breast cancer were randomised to nine cycles of granulocyte colony-stimulating factor supported and individually tailored FEC (5-fluorouracil, epirubicin, cyclophosphamide), (n = 251) or standard FEC followed by marrow-supported high-dose therapy with CTCb (cyclophosphamide, thiotepa, carboplatin) therapy (n = 274), followed by locoregional radiotherapy and tamoxifen for 5 years. Results: There were 104 breast cancer relapses in the tailored FEC group versus 139 in the CTCb group (double triangular method by Whitehead, P = 0.046), with a median follow-up of all included patients of 60.8 months. The event-free survival demonstrated 121 and 150 events in the tailored FEC- and CTCb ...
N Engl J Med. 2009 Aug 19; Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka MBACKGROUND: Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer. METHODS: In this phase 3, open-label study, we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers or former light smokers to receive gefitinib (250 mg per day) (609 patients) or carboplatin (at a dose calculated to produce an area under the curve of 5 or 6 mg per milliliter per minute) plus paclitaxel (200 mg per square meter of body-surface area) (608 patients). The primary end point was progression-free survival. RESULTS: The 12-month rates of progression-free survival were 24.9% with gefitinib and 6.7% with ...
Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia. The presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib. (ClinicalTrials.gov number, N …
GOG 175 - Ovary - A Randomized Phase III Trial Of IV Carboplatin (AUC 6) and Paclitaxel 175 MG/M2 Q 21 Days X 3 Courses Plus Low-Dose Paclitaxel 40 MG/M2 Weekly VS. Carboplatin (AUC 6) and Paclitaxel 175MG/M2 Q21 Days X 3 Courses in Patients With Early Stage Ovarian ...
Clinical Trials - clinicaltrials.gov This is a multi-institutional Phase I dose-escalation and dose-expansion trial for patients with advanced, solid tumor mali...
Title. Comparing the Effectiveness of Different Drug Combinations for Advanced Cancer of the Urothelium Which Cannot Be Controlled With Surgery (A Phase III Trial). Sponsor. Eastern Cooperative Oncology Group through the NCI-sponsored Cancer Cooperative Group Program. Purpose of the Study. To slow, stop or decrease the growth of cancer of the urothelium and to compare and evaluate the effectiveness of the two drug treatments. The two treatments were; 1) a Two-Drug (paclitaxel and carboplatin) Combination Chemotherapy, and 2) a Four-Drug (methotrexate, vinblastine, asplatin, doxorubin) Combination Chemotherapy. The urothelium is the lining of the kidney, ureter, bladder, or lining of the urinary tract.. Results. The study did not show one treatment to be more beneficial than the other. Of patients receiving the four-drug combination, 12.8 percent experienced a complete response rate (no detectable cancer remaining) and 23.1 percent experienced a decrease in the size or extent of their cancer ...
Inclusion/exclusion criteria. Requirements for enrollment in the trial included histologic proof of advanced solid tumor malignancy with no hope of curative, or clearly established life-prolonging, therapy; age ,18 years; performance status 0 to 2; life expectancy ,3 months; ability to accomplish informed consent; WBC ,3,500; ANC ,1,700; PLT ,100,000; normal direct bilirubin; and creatinine, alkaline phosphotase, aspartate aminotransferase, and alanine aminotransferase ,2.5× UNL. Exclusion criteria included radiation to ,25% bone marrow, prior cisplatin or carboplatin therapy; chemotherapy, biological, immunotherapy, or radiotherapy within the past 4 weeks (6 weeks for mitomycin C/nitrosoureas); New York Heart Association class III or IV or history of angina; central nervous system metastases or seizure disorder; pregnancy/lactation; and grade ,1 peripheral neuropathy.. Treatment cohorts and schedules. Patients were enrolled in three sequential cohorts. In cohort/stage I, cisplatin was fixed at ...
"Carboplatin dosing". Center for Drug Evaluation and Research. Food and Drug Administration. Archived from the original on 2011- ... new FDA guidelines have suggested limiting doses to specified maxima with carboplatin, a chemotherapy drug. A 2009 Japanese ...
Others include carboplatin and oxaliplatin. These compounds are capable of crosslinking DNA, and kill cells by similar pathways ... Compounds containing platinum, such as cisplatin, oxaliplatin and carboplatin, are applied in chemotherapy against certain ...
p. 9. "Carboplatin: Chemistry for Fighting Cancer". Johnson Matthey.{{cite web}}: CS1 maint: url-status (link) "Scientific ... A blue plaque commemorating the work of the Institute for Cancer Research, including the discovery of Carboplatin, was erected ... JM8 was identified and successfully launched as Carboplatin (Paraplatin) by Bristol Myers Squibb in 1986. This achievement was ... He is credited with the discovery of Carboplatin, JM 216 (Satraplatin), and AMD 473. A collaboration with Johnson Matthey ...
This has no effect on carboplatin. It also increases the AUC of docetaxel, doxorubicin and irinotecan but decreases the AUC of ... Plasma concentration of sorafenib and paclitaxel may be increased when the drugs are co-administered along with carboplatin. ... is used as a first-line treatment in combination with paclitaxel and carboplatin. It can also be used in the treatment for ... of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian ...
Carboplatin Dicycloplatin "Cisplatin Use During Pregnancy". Drugs.com. 12 September 2019. Retrieved 25 February 2020. " ...
Cisplatin and etoposide, Carboplatin and etoposide. The drug paclitaxel may be useful in the treatment of cisplatin-resistant ... In this study, patients with ES-SCLC were treated with standard carboplatin plus etoposide and were randomized to receive ... In cases of LS-SCLC, combination chemotherapy (usually cisplatin or carboplatin plus etoposide) is administered together with ... January 2019). "Combination therapy with carboplatin and paclitaxel for small cell lung cancer". Respiratory Investigation. 57 ...
carboplatin/ paclitaxel as a first-line treatment in advanced NSCLC. IPASS studied 1,217 patients with confirmed adenocarcinoma ... September 2009). "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma". The New England Journal of Medicine. 361 ( ... September 2009). "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma". The New England Journal of Medicine. 361 ( ...
Bone marrow suppression is the dose-limiting toxicity of carboplatin. Carboplatin is much less damaging to kidneys compared to ... Carboplatin Carboplatin, like cisplatin, is composed of a central atom of platinum and two ammonia molecules, but it has a ... December 2006). "Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer". New England Journal of ... These two studies made significant impact on the chemotherapy choices for treating NSCLC, with cisplatin or carboplatin as the ...
"A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in ... In March 2019, it was approved in the United States, in combination with carboplatin and etoposide, for the first-line ... "FDA approves atezolizumab with nab-paclitaxel and carboplatin for metastatic NSCLC without EGFR/ALK aberrations". U.S. Food and ... The chemotherapy used was Carboplatin, and Paclitaxel. Median overall survival was 19.8 and 14.9 months for patients treated ...
Carboplatin: 4 and busulfan dosing rely upon results from blood tests to calculate the optimal dose for each person. Simple ... Drugs with medium risk include doxorubicin and platinum analogs such as cisplatin and carboplatin. On the other hand, therapies ... Aziridines include thiotepa, mytomycin and diaziquone (AZQ). Cisplatin and derivatives include cisplatin, carboplatin and ...
The major elements are cisplatin, carboplatin, and oxaliplatin. It has been reported with full recovery among early-stage ...
Cisplatin ("Platinol") was given instead of carboplatin ("Paraplatin"). He resided in Rome, New York with his second wife, ...
Metal-Ammine Complexes Carboplatin, a widely used anticancer drug. Pentamminerhodium chloride, the dichloride salt of a ...
"AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer". Clinicaltrials.gov. 19 October 2019. "Trial shows benefit of ' ... ". "Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel". ...
A combination of carboplatin and paclitaxel is often used. Advances techniques such as FISH and tissue of origin testing may ...
Kang SJ, Durairaj C, Kompella UB, O'Brien JM, Grossniklaus HE (August 2009). "Subconjunctival nanoparticle carboplatin in the ... December 2009). "Does a nanomolecule of Carboplatin injected periocularly help in attaining higher intravitreal concentrations ... carboplatin) has been developed, which has shown promising results in the treatment of retinoblastoma in animal models without ...
ClinicalTrials.gov identifier NCT01690468: "Triciribine and Carboplatin in Ovarian Cancer". Clinicaltrials.gov. U.S. National ...
2016). "Adaptive randomization of veliparib-carboplatin treatment in breast cancer." New England Journal of Medicine 375 (1): ...
Either cisplatin or carboplatin is used as the platinum backbone. Development of targeted therapies has been less rapid for ...
Other platinum-containing anticancer drugs include cisplatin, carboplatin, and oxaliplatin. Triplatin belongs to the anticancer ...
Typical chemotherapy agents are a combination of paclitaxel and carboplatin. Cetuximab is also used in the treatment of throat ...
In contrast to other drugs of the platinum-based antineoplastic class of drugs cisplatin and carboplatin, oxaliplatin features ... Oxaliplatin has less ototoxicity and nephrotoxicity than cisplatin and carboplatin. The compound features a square planar ...
Carboplatin may be associated with a higher risk of thrombocytopenia. Cisplatin may cause more nausea or vomiting when compared ... December 2006). "Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer". The New England Journal of ... Carboplatin is a chemotherapy agent that has a similar effect on a person's survival when compared to cisplatin, and has a ... "Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer". The Cochrane ...
Study of Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC, 26 February 2020 First Patient in ... "Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC". clinicaltrials.gov. 26 February 2020. Retrieved ... for use in combination with carboplatin for the treatment of patients with CCR5-positive mTNBC. In July 2019, CytoDyn announced ...
... and in combination with carboplatin-pemetrexed chemotherapy compared to carboplatin-pemetrexed. "Rybrevant Product information ...
Rebimastat was used in a Paclitaxel/Carboplatin treatment in phase III. The results of the trial was a higher incidence of ...
Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer". New England Journal of Medicine. 374 (8): 738-748. doi:10.1056/ ...
Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for ... Carboplatin - a platinum-based antineoplastic drug, also an alkylating antineoplastic agent; Etoposide - a topoisomerase ...
"Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC". clinicaltrials.gov. Retrieved 2019-02-19. " ...
Lokich J, Anderson N (January 1998). "Carboplatin versus cisplatin in solid tumors: an analysis of the literature". Ann. Oncol ... Go RS, Adjei AA (January 1999). "Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin". J ... pylori cisplatin and carboplatin - platinum containing anticancer agents gold salts such as auranofin - anti-inflammatory for ...
Carboplatin Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Carboplatin may cause severe allergic reactions. If you experience an allergic reaction to carboplatin injection, it may begin ... Before receiving carboplatin injection,. *tell your doctor and pharmacist if you are allergic to carboplatin, cisplatin ( ... If you become pregnant while receiving carboplatin, call your doctor. Carboplatin may harm the fetus. ...
Adding carboplatin or bevacizumab to standard neoadjuvant chemotherapy for triple-negative breast cancer improves pathologic ... carboplatin to the area under the curve (AUC) 6 every 3 weeks for 4 cycles; or both carboplatin and bevacizumab. ... "Should carboplatin be routinely added to stage II or III triple-negative breast cancer? With the caveat...that we do not have ... He explained that carboplatin improved the pCR rate, but it is not known if that will result in significant improvement in ...
After 24 hours, close to 70% of carboplatin is excreted in the urine unchanged. This means that the dose of carboplatin must be ... Unlike cisplatin, carboplatin may be susceptible to alternative mechanisms. Some results show that cisplatin and carboplatin ... For this reason, "CBDCA" is sometimes used in the medical literature as an abbreviation referring to carboplatin. Carboplatin ... The diminished reactivity limits protein-carboplatin complexes, which are excreted. The lower excretion rate of carboplatin ...
Carboplatin (carboplatin recipe) - Learn more about Carboplatin. Next page: CARBOPLATIN NEWS She should lifelessly be referred ... CARBOPLATIN .:.:.:. Find the Best Deals for carboplatin?. carboplatin price list, carboplatin street price, medical treatment, ... carboplatin online, i want to buy cheap carboplatin, carboplatin calculator, elizabeth carboplatin. Diazapam is a widely used ... carboplatin extravasation, carboplatin package insert, carboplatin georgia, i wanna buy cheap carboplatin. Foreign Drugstores ...
This carboplatin dosing calculator uses the Calvert method to calculate the total carboplatin dose needed to achieve a given ... This carboplatin dosing calculator uses the Calvert method to calculate the total carboplatin dose needed to achieve a given ... Carboplatin dosage: prospective evaluation of a simple formula based on renal function. ... Carboplatin dosage: prospective evaluation of a simple formula based on renal function. ...
Peripheral neuropathy is uncommon when conventional doses of carboplatin are used, but patients over 65 years of age... ... Carboplatin: Side Effects, Warnings and What to Avoid. This is not all the information you need to know about carboplatin for ... Carboplatin is a platinum-based chemotherapy agent, but neuropathy symptoms with carboplatin treatment tend to be mild in most ... If carboplatin is combined with other neurotoxic cancer treatments, or used at higher doses or for prolonged periods, the risk ...
Carboplatin is used to treat testicular, ovarian and breast cancer; ... Carboplatin is a platinum-based antineoplastic drug that damages DNA by forming intrastrand cross-links with neighboring ... Carboplatin has been used:. *in chemotherapy-induced thrombocytopenia mouse model and treatment ...
This page contains information on the chemical Carboplatin including: 41 synonyms/identifiers. ... Carboplatin*Carboplatin (JAN/USP) *Carboplatin (USAN) *Carboplatin [USAN:BAN:INN:JAN]*Carboplatine [French]*Carboplatino [ ... Carboplatin (EnvironmentalChemistry.com),/a,- This page contains information on the chemical Carboplatin including: 41 synonyms ... Carboplatin. Identifications. *CAS Number: 41575-94-4*Synonyms/Related:*(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)- ...
If your search becomes too narrow (finds too few studies), broaden it by removing search terms with the Modify Search page ...
Approval for UK reolysin/ paclitaxel and carboplatin trial. Oncolytics Biotech has received a letter of approval from the UK ... non-randomised study of reolysin given intravenously with paclitaxel and carboplatin every three weeks. A maximum of three ... recommended dose and dosing schedule and safety profile of reolysin when administered in combination with carboplatin and ... of a further 12 patients at the maximum dosage of reolysin in combination with standard dosages of paclitaxel and carboplatin. ...
Drug: Carboplatin A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on ... Drug: Carboplatin A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on ... Drug: Carboplatin A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on ... Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers. The safety and scientific validity of ...
... and carboplatin (Paraplatin)-is better for the treatment of advanced ovarian cancer because it is significantly less toxic in ... Not only does this study prove that carboplatin is at least as effective as cisplatin, but it presents fewer troublesome side ... The paclitaxel/carboplatin regimen was well tolerated by patients and caused fewer gastrointestinal, genitourinary, and ... There were concerns that carboplatin would be less effective when compared to cisplatin, the drug that had been previously used ...
Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer ( ... Publikace , Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in .... ... Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer ( ... title = {Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung ...
Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of ... Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter ... Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer. ... Phase II trial of daily low-dose carboplatin and thoracic radiotherapy in elderly patients with locally advanced non-small cell ...
We reduced his carboplatin dose after dose #1 and saw no changes on his CBC so we increased it slightly for dose #3 (but still ... Add Reply: Chemotherapy Lesson (Carboplatin) Please add brief descriptive title for new topics. Titles like "Worried" or "Need ... Based on his previous doses we check a CBC on day 9 and 14 - at his highest dose of carboplatin the WBCs started to drop on day ... Grover had his #3 dose of carboplatin 16 days ago before we had a weekend trip planned. ...
Adding carboplatin to neoadjuvant paclitaxel significantly improves event-free survival in patients with triple-negative breast ... Compared with paclitaxel plus carboplatin, the HR for EFS was 1.12 for paclitaxel plus carboplatin and veliparib (95% CI, 0.72- ... Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone ... 1.25 for paclitaxel plus carboplatin and veliparib vs paclitaxel and carboplatin (95% CI, 0.70-2.24, P =.46). ...
Drug Information available for: Vincristine sulfate Etoposide Carboplatin Etoposide phosphate Genetic and Rare Diseases ... Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed ... GROUP 1 (high-risk features): Patients receive vincristine IV and carboplatin IV over 1 hour on day 1 and etoposide IV over 1 ... Patients who require chemotherapy receive vincristine IV and carboplatin IV over 1 hour on day 1 and etoposide IV over 1 hour ...
We administered carboplatin by addition to the fishs tank water or their food. One week of treatment with 100 μM carboplatin ... Electrochemical Measurement of Dopamine Release and Uptake in Zebrafish Following Treatment with Carboplatin. ... evoked dopamine release and uptake in whole brain preparations from zebrafish that have been treated with carboplatin, an agent ... spectroscopy measurements suggested that administration through food resulted in higher initial levels of carboplatin compared ...
Watch Daisee Dog receive carboplatin chemotherapy for treating osteosarcoma at the Veterinary Cancer Group of Southern ... Tags amputation, bone cancer, canine, carboplatin, chemotherapy, dog, oncology, osteosarcoma, three-legged, Treatment, tripod, ... and the VCG staff allowed us to witness all of the steps involved in measuring and administering the carboplatin dose Daisee ...
Hypersensitivity reactions to carboplatin and cisplatin in non-small cell lung cancer. Journal of thoracic disease 2013 Apr;5; ...
... carboplatin use different ways to stop tumor cells from dividing so th ... disodium and carboplatin, as measured by the complete and partial tumor response rate,. in patients with extensive stage small ... Arm II: Patients receive pemetrexed disodium as in arm I and carboplatin IV over 1 hour. on day 1.. In both arms, courses ... A Randomized Phase II Trial Of ALIMTA/Cisplatin And ALIMTA/Carboplatin In Extensive Stage Small Cell Lung Cancer. Trial Phase: ...
... treated with amputation and carboplatin, vs those treated with amputation, carboplatin, and high-dose vitamin C. ... If you agree to participate, your pet will be randomized to receive 4 doses of standard-of-care chemotherapy (IV carboplatin) ... or carboplatin plus IV high-dose vitamin C. Each dose is given 3 weeks apart. ...
RESULTS: The treatment regimen of weekly paclitaxel (100 mg/m for 3 of 4 weeks) and carboplatin (area under the curve = 6 mg/ml ... RESULTS: The treatment regimen of weekly paclitaxel (100 mg/m for 3 of 4 weeks) and carboplatin (area under the curve = 6 mg/ml ... RESULTS: The treatment regimen of weekly paclitaxel (100 mg/m for 3 of 4 weeks) and carboplatin (area under the curve = 6 mg/ml ... RESULTS: The treatment regimen of weekly paclitaxel (100 mg/m for 3 of 4 weeks) and carboplatin (area under the curve = 6 mg/ml ...
T1 - Comparison of conventional dose and double dose carboplatin in patients receiving cyclophosphamide plus carboplatin for ... Comparison of conventional dose and double dose carboplatin in patients receiving cyclophosphamide plus carboplatin for ... Comparison of conventional dose and double dose carboplatin in patients receiving cyclophosphamide plus carboplatin for ... Comparison of conventional dose and double dose carboplatin in patients receiving cyclophosphamide plus carboplatin for ...
Carboplatin is a platinum alkylating agent that interferes with the function of DNA by producing interstrand DNA cross-links. ... Iwasaki K, Obara W, Kato Y, Takata R, Tanji S, Fujioka T. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder ... Carboplatin has black box warnings, including bone marrow suppression, anaphylactic reactions, and vomiting. ...
PF-05212384, Carboplatin, Paclitaxel. Description: starting dose of PF-05212384: 95 mg iv weekly Dose of Carboplatin: 5 AUC ... Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced ... Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor. May 27, 2020. ... Successive cohorts of patients will receive escalating doses of PF-05212384 in combination with paclitaxel and carboplatin, ...
... of renal function is warranted in patients who would otherwise have their estimated glomerular filtration rate and carboplatin ... They said consistent guidelines on calculating carboplatin doses are warranted.. Howell SJ, Coe F, Wang X, Horsley L, Ekholm M ... The authors said the high pCR rates in the study, particularly for the ER+/HER2+ subgroup, show that carboplatin is an ... However, they said, the results caution against the temptation to reduce the carboplatin dose in TCHP to area under the curve 5 ...
... carboplatin), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, ... encoded search term (carboplatin ((carboplatin))) and carboplatin ((carboplatin)) What to Read Next on Medscape ... carboplatin and cisplatin both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.. carboplatin, cisplatin. Either ... carboplatin and streptozocin both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.. carboplatin, streptozocin. ...
NiraParib Maintenance After Carboplatin and Paclitaxel in optimaLly de * IMGN853 With Carboplatin in Second-line Treatment of ... With Bevacizumab, Carboplatin, PLD, Pembrolizumab, or Bevacizumab + Carboplatin in Adults With FRa + Adv. EOC, Primary ... carboplatin as in Arm I. ARM IV: Patients receive gemcitabine hydrochloride IV as in Arm III, bevacizumab IV and carboplatin IV ... Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse ...
  • Carboplatin injection must be given in a hospital or medical facility under the supervision of a doctor who is experienced in giving chemotherapy medications for cancer. (medlineplus.gov)
  • and the high pCR rates in pilot studies in which carboplatin was added to standard chemotherapy in patients with triple-negative tumors. (medscape.com)
  • Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. (wikipedia.org)
  • Carboplatin is a platinum-based chemotherapy agent, but neuropathy symptoms with carboplatin treatment tend to be mild in most cases. (drugs.com)
  • These findings, overall, support the inclusion of carboplatin into neoadjuvant chemotherapy for stage II-III triple-negative breast cancer patients, regardless of the germline BRCA status," Dr Loibl concluded. (empr.com)
  • Drugs used in chemotherapy, such as vincristine, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. (clinicaltrials.gov)
  • Estimate the EFS and OS of patients with specific high-risk features who are uniformly treated with adjuvant chemotherapy comprising vincristine, carboplatin, and etoposide. (clinicaltrials.gov)
  • Patients who require chemotherapy receive vincristine IV and carboplatin IV over 1 hour on day 1 and etoposide IV over 1 hour on days 1 and 2. (clinicaltrials.gov)
  • If you agree to participate, your pet will be randomized to receive 4 doses of standard-of-care chemotherapy (IV carboplatin) or carboplatin plus IV high-dose vitamin C. Each dose is given 3 weeks apart. (iastate.edu)
  • The authors said the high pCR rates in the study, particularly for the ER+/HER2+ subgroup, show that carboplatin is an important chemotherapy option in the treatment for early HER2+ breast cancer . (medscape.com)
  • Carboplatin is a platinum-based chemotherapy drug. (guidetopharmacology.org)
  • The addition of cyclosporine in combination with chemotherapy regimen of carboplatin, etoposide, and vincristine reportedly have showed enhanced efficacy of chemotherapy. (medscape.com)
  • IMSEAR at SEARO: Benefit of electrocardiography during front-line combination paclitaxel and carboplatin chemotherapy for epithelial ovarian cancer. (who.int)
  • Kietpeerakool C, Tiyayon J, Suprasert P, Kanjanavanit R, Srisomboon J. Benefit of electrocardiography during front-line combination paclitaxel and carboplatin chemotherapy for epithelial ovarian cancer. (who.int)
  • OBJECTIVE: To evaluate the patterns of electrocardiography (ECG), cardiac risk factors and its clinical consequence in women with epithelial ovarian cancer (EOC) who received paclitaxel and carboplatin (PC) as front line chemotherapy. (who.int)
  • CONCLUSION: Although paclitaxel and carboplatin chemotherapy could induce abnormal ECG in women with either normal or abnormal prior ECG, its consequence was of no clinical significance. (who.int)
  • Purpose This is the first randomized phase II/III trial comparing two carboplatin-based chemotherapy regimens in patients with urothelial cancer who are ineligible ("unfit") for cisplatin chemotherapy. (warwick.ac.uk)
  • A Phase II, randomised, open-label study of Gemcitabine/Carboplatin first-line chemotherapy in combination with or without the antisense oligonucle. (esmo.org)
  • This study investigated whether the combination of Apatorsen and chemotherapy (GC+A) can improve the outcome of patients with advanced SCC compared to treatment with gemcitabine/carboplatin (GC) alone. (esmo.org)
  • it seems clear through multiple studies that carboplatin improves the pCR (pathological complete response rate) in women having NAC (neoadjuvant or preoperative chemotherapy) in the setting of triple negative breast cancer. (drshanewhite.com)
  • In addition, the interaction of GM-CSF and chemotherapy, especially carboplatin-based, may be more complex than originally anticipated. (elsevier.com)
  • following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see section 5.1) - following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel - in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. (who.int)
  • Conclusion: Carboplatin plus paclitaxel combination chemotherapy is effective in patients with predominantly nodal/pleural metastases of unknown primary carcinoma and in women with peritoneal carcinomatosis. (ucy.ac.cy)
  • Carboplatin is a drug used in chemotherapy cancer treatments for a variety of cancers. (ihealthdirectory.com)
  • This trial is looking at a new drug called LY2940680 with carboplatin and etoposide chemotherapy for small cell lung cancer that has spread beyond the lungs. (cancerresearchuk.org)
  • Chemotherapy (carboplatin and paclitaxel) was given weekly (for 7 weeks), concurrently with radiation. (uthscsa.edu)
  • The primary objective of the study was to evaluate whether progression-free survival (PFS) was prolonged with the addition of veliparib to standard platinum-based chemotherapy (carboplatin/paclitaxel [C/P]) and continued as maintenance therapy compared with chemotherapy alone. (ucsd.edu)
  • Ovarian tumor initiating cell populations persist following paclitaxel and carboplatin chemotherapy treatment in vivo. (semanticscholar.org)
  • Introduction: In cohort G of KEYNOTE-021 (NCT02039674), first-line pembrolizumab plus pemetrexed-carboplatin significantly improved the objective response rate and progression-free survival versus chemotherapy alone with manageable toxicity in advanced nonsquamous NSCLC. (elsevier.com)
  • Conclusions: First-line pembrolizumab plus pemetrexed-carboplatin continued to show improved response and survival versus chemotherapy alone in advanced nonsquamous NSCLC, with durable clinical benefit in patients who completed 2 years of therapy. (elsevier.com)
  • The hypothesis is that amivantamab, when given in combination with standard of care carboplatin-pemetrexed chemotherapy, will prolong PFS compared with carboplatin-pemetrexed in patients with locally advanced or metastatic NSCLC characterized by EGFR Exon 20ins activating mutations. (uccancer.org)
  • The proportion of patients showing CR was low in the carboplatin (CBDCA)- and oxaliplatin-based chemotherapy groups, especially among women. (researchsquare.com)
  • The Gynecologic Oncology Group (GOG)-0218 trial was a Phase III randomized, double-blind, placebo-controlled trial with three arms that examined the significance of BV in combination with standard chemotherapy using paclitaxel + carboplatin (TC therapy). (dovepress.com)
  • Initial dose of 4 mg/kg as an intravenous infusion over 90 minutes then at 2 mg/kg as an intravenous infusion over 30 minutes weekly during chemotherapy for the first 12 weeks (paclitaxel or docetaxel) or 18 weeks (docetaxel and carboplatin). (drugs.com)
  • OTCQX: RHHBY) today announced positive results from the Phase III IMpower133 study of Tecentriq® (atezolizumab) plus carboplatin and etoposide (chemotherapy) for the initial (first-line) treatment of people with previously-untreated extensive-stage small cell lung cancer (ES-SCLC). (globenewswire.com)
  • IMpower133 is a Phase III, multicentre, double-blinded, randomised placebo-controlled study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy (carboplatin and etoposide) versus chemotherapy (carboplatin plus etoposide) alone in chemotherapy-naïve people with ES-SCLC. (globenewswire.com)
  • RATIONALE: Drugs used in chemotherapy, such as cisplatin, vincristine, bleomycin, carboplatin, and etoposide phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. (druglib.com)
  • cell tumors treated with intensive induction chemotherapy comprising cisplatin, vincristine, bleomycin, and carboplatin followed by bleomycin, etoposide phosphate, and cisplatin (BEP) vs standard BEP chemotherapy. (druglib.com)
  • The chemotherapy arm included pemetrexed plus carboplatin or pemetrexed plus cisplatin. (curetoday.com)
  • This was a phase III randomized trial of patients who received first-line platinum-based chemotherapy with either cisplatin or carboplatin backbones. (medpagetoday.com)
  • The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating germ cell tumors. (stanford.edu)
  • The patient had received 4 cycles of chemotherapy with carboplatin, pemetrexed, and pembrolizumab for progressive disease and was currently in maintenance with pemetrexed-pembrolizumab. (researchgate.net)
  • NICE noted that clinical trial evidence suggests that Tecentriq with carboplatin and etoposide increases the time before the disease worsens by around a month compared with standard chemotherapy (5.2 months versus 4.3 months respectively). (pharmaphorum.com)
  • It also suggests that Tecentriq plus carboplatin and etoposide increases overall survival compared with standard chemotherapy. (pharmaphorum.com)
  • OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC). (worldpharmanews.com)
  • IMpower150 is a multicentre, open-label, randomised, controlled Phase III study evaluating the efficacy and safety of TECENTRIQ in combination with carboplatin and paclitaxel with or without Avastin in people with stage IV non-squamous NSCLC who had not been treated with chemotherapy for their advanced disease. (worldpharmanews.com)
  • This phase III trial is studying vincristine, carboplatin, and etoposide to see how well they work compared to observation only in treating patients who have undergone surgery for newly diagnosed retinoblastoma. (clinicaltrials.gov)
  • GROUP 1 (high-risk features): Patients receive vincristine IV and carboplatin IV over 1 hour on day 1 and etoposide IV over 1 hour on days 1 and 2. (clinicaltrials.gov)
  • Visual field was performed in thirteen patients affected by cerebral neoplasms after treatment with intra-arterial Carboplatin and Etoposide therapy, in order to evaluate a possible toxic effect. (elsevier.com)
  • Two years ago I was given Carboplatin and Etoposide (VP16) for sclc. (lungevity.org)
  • This phase II trial studies the effect of polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide as initial salvage therapy in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). (survivornet.com)
  • I. Evaluate the safety and tolerability of polatuzumab vedotin (Pola) added to rituximab, ifosfamide, carboplatin, and etoposide (PolaR-ICE) as first salvage therapy for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). (survivornet.com)
  • SALVAGE THERAPY: Patients receive polatuzumab vedotin intravenously (IV) on day 1, rituximab IV on day 1, etoposide IV on days 1-3, carboplatin IV on day 2, and ifosfamide IV on day 2 or days 1-3. (survivornet.com)
  • One combination of drugs they use is carboplatin and etoposide . (cancerresearchuk.org)
  • In this trial some people will have LY2940680 with carboplatin and etoposide. (cancerresearchuk.org)
  • with carboplatin and etoposide. (cancerresearchuk.org)
  • In part 1, the first few people will have a low dose of LY2940680 with carboplatin and etoposide. (cancerresearchuk.org)
  • You have etoposide and carboplatin as an injection into a vein . (cancerresearchuk.org)
  • In 2004, the Gynecologic Oncology Group (GOG) published their experience using carboplatin and etoposide in ovarian dysgerminomas. (medscape.com)
  • This regimen is carboplatin at 400 mg/m 2 on day 1 and etoposide at 120 mg/m 2 on days 1-3 q4wk for 3 cycles. (medscape.com)
  • Given the improvement in OS, the first in decades, the investigators suggested that atezolizumab plus carboplatin and etoposide be considered the new standard of care for first-line treatment of ES-SCLC. (medscape.com)
  • This phase III trial studies how well active surveillance, bleomycin, etoposide, carboplatin or cisplatin work in treating pediatric and adult patients with germ cell tumors. (stanford.edu)
  • Around 2,400 people in England have ES-SCLC, of whom around 1,200 people will be eligible to receive Tecentriq plus carboplatin and etoposide. (pharmaphorum.com)
  • In clinical studies when ​​a carboplatin regimen was compared to a cisplatin regimen in 393 patients for the treatment of ovarian cancer , peripheral neuropathy occurred in 16% of patients receiving the carboplatin regimen compared to 42% in the cisplatin regimen arm, a significant difference. (drugs.com)
  • Carboplatin is used to treat testicular, ovarian and breast cancer. (sigmaaldrich.com)
  • Oncolytics Biotech, a TSX-listed Canadian biotechnology company, has received a letter of approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its clinical trial application to test intravenous administration of reolysin in combination with paclitaxel and carboplatin in patients with advanced melanoma, lung and ovarian cancers. (pmlive.com)
  • Olaparib has been given safely in combination with carboplatin, a drug used to treat breast, ovarian, uterine, and cervical cancer, but more research is needed to determine whether the drugs are more effective when given together or which drug should be given first. (clinicaltrials.gov)
  • A landmark study showed that a new drug combination-paclitaxel (Taxol) and carboplatin (Paraplatin)-is better for the treatment of advanced ovarian cancer because it is significantly less toxic in patients. (cancernetwork.com)
  • Between March 1992 and November 1994, 91 patients with stage III and IV ovarian carcinoma were enrolled in a randomized comparative study of cyclophosphamide 600 mg/m 2 plus carboplatin 300 mg/m 2 vs. cyclophosphamide 600 mg/m 2 plus carboplatin 600 mg/m 2 , each regimen given monthly for six cycles. (elsevier.com)
  • A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. (checkorphan.org)
  • This randomized phase III trial studies carboplatin, paclitaxel and gemcitabine hydrochloride when given together with or without bevacizumab after surgery to see how well it works in treating patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer that has come back. (checkorphan.org)
  • To determine if the addition of bevacizumab to the second-line and maintenance phases of treatment increases the duration of overall survival relative to second-line paclitaxel and carboplatin alone in patients with recurrent platinum sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer. (checkorphan.org)
  • The study will be conducted in adult patients with advanced breast, NSCLC, ovarian or endometrial, small cell lung cancer (SCLC) and Head and Neck (HNSCC) cancer for whom there is an indication to the use of paclitaxel and carboplatin. (checkorphan.org)
  • Histological or cytological diagnosis of advanced/metastatic breast, NSCLC, ovarian and endometrial, small cell lung cancer (SCLC) and Head and Neck (HNSCC) cancer for which there is an indication to the use of paclitaxel and carboplatin. (checkorphan.org)
  • We aimed to assess whether trebananib, a peptibody that inhibits binding of angiopoietin 1 and 2 to Tie2, improved progression-free survival when added to carboplatin and paclitaxel as first-line therapy in advanced epithelial ovarian, primary fallopian tube, or peritoneal cancer in a phase 3 clinical trial. (elsevier.com)
  • Interpretation: Trebananib plus carboplatin and paclitaxel did not improve progression-free survival as first-line treatment for advanced ovarian cancer. (elsevier.com)
  • We assessed activity and safety of pembrolizumab with carboplatin in recurrent platinum-resistant ovarian cancer. (bmj.com)
  • Patients and methods This phase I/II, single-arm clinical trial studied concurrent carboplatin and pembrolizumab in recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer. (bmj.com)
  • Conclusions Pembrolizumab with carboplatin was well-tolerated and active in recurrent platinum-resistant ovarian cancer. (bmj.com)
  • Carboplatin is used for Advanced Ovarian Cancer, Lung Cancer, Bladder Cancer, Uterus Cancer, Head And Neck Cancer, Cervical Or Testicular Cancer and other conditions. (medzeellifescience.com)
  • Objective: This study aimed to evaluate intravenous (IV)/intraperitoneal (IP) paclitaxel and IP carboplatin (TCipTip therapy) feasibility in epithelial ovarian (EOC), fallopian tube (FTC), or peritoneal carcinoma (PC) patients. (elsevier.com)
  • Ascites cells from patients with papillary serous ovarian cancer were isolated and treated with 1 μ M WNT974±100 μ M carboplatin. (nature.com)
  • This study found that KRT17 could increase the carboplatin resistance of ovarian cancer cells by regulating the AKT/mTOR pathway, promoting the cycle process of ovarian cancer cells, and inhibit apoptosis. (ejgo.net)
  • Ovarian cancer immunotherapy en route: IL9 inhibits growth of ovarian cancer and upregulates its expression of Ox40L and 4-1BBL. (ejgo.net)
  • In this study we have compared the pharmacokinetics and myelotoxicity of carboplatin administered at 18.00 and 06.00 in random order in patients with advanced ovarian carcinoma. (ox.ac.uk)
  • We report that recurrent ovarian carcinomas after paclitaxel/carboplatin treatment have higher levels of spleen tyrosine kinase (SYK) and phospho-SYK. (nih.gov)
  • Calvert formula: D o s e ( m g ) = A U C ⋅ ( G F R + 25 ) {\displaystyle \mathrm {Dose} (\mathrm {mg} )=\mathrm {AUC} \cdot (\mathrm {GFR} +25)} The typical area under the curve (AUC) for carboplatin ranges from 3-7 (mg/ml)*min. (wikipedia.org)
  • RESULTS: The treatment regimen of weekly paclitaxel (100 mg/m for 3 of 4 weeks) and carboplatin (area under the curve = 6 mg/ml/min once every 4 weeks) (arm 1) was associated with the best therapeutic index overall. (elsevier.com)
  • The delivered area under the curve (dAUC) was calculated ([actual carboplatin dose at cycle 1÷dose calculated with uncapped/unbanded eGFR]×6) and dichotomised at the median value. (medscape.com)
  • However, they said, the results caution against the temptation to reduce the carboplatin dose in TCHP to area under the curve 5 as this is likely to reduce the pCR rate. (medscape.com)
  • Pembrolizumab 200 mg was given on day 1 and carboplatin area under the curve 2 on days 8 and 15 of a 3-week cycle until progression. (bmj.com)
  • median age, 60 years) were treated with carboplatin at target area under the curve 6 mg/mL/min followed by paclitaxel 200 mg/m2 as a 3-hour infusion and granulocyte colony-stimulating factor from days 5 to 12. (ucy.ac.cy)
  • Treatment consisted of paclitaxel 175 mg/m 2 , carboplatin area under the curve 6 mg/mL/min, and bevacizumab 15 mg/kg every 21 days until disease progression, complete remission, or limiting toxicity. (elsevier.com)
  • The arms that were eventually incorporated into the registration KEYNOTE-522 study (solvent-based paclitaxel was the taxane used) had pCR rates of 25% (carboplatin area under the curve of 2 [AUC2]) and 50% (carboplatin AUC5) in KEYNOTE-173. (jnccn.org)
  • I prefer carboplatin with an AUC [area under the curve] calculation of 6. (pharmacytimes.com)
  • The catch is that bevacizumab adds only an incremental benefit, does not have synergistic activity with carboplatin, and is associated with significantly increased toxicities that could outweigh the benefit, said William M. Sikov, MD, from the Warren Alpert Medical School of Brown University in Providence, Rhode Island. (medscape.com)
  • or both carboplatin and bevacizumab. (medscape.com)
  • To identify molecular determinants that predict sensitivity or resistance to carboplatin and paclitaxel with or without bevacizumab followed with or without maintenance bevacizumab therapy. (checkorphan.org)
  • Objective: We evaluated the efficacy and safety of the combination of paclitaxel, carboplatin, and bevacizumab in patients with advanced or recurrent cervical cancer. (elsevier.com)
  • Conclusion: The combination of paclitaxel, carboplatin, and bevacizumab is effective and safe in patients with advanced or recurrent cervical cancer. (elsevier.com)
  • U.S., March 10 -- ClinicalTrials.gov registry received information related to the study (NCT03071848) titled 'A Study to Evaluate Safety and Effectiveness of Bevacizumab in Combination With Paclitaxel and Cisplatin/Carboplatin or Toptecan in Participants With Advanced Cervical Cancer' on March 2. (shine.com)
  • Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. (rush.edu)
  • The purpose of this study is to find the safest dose of tisotumab vedotin that can be given with bevacizumab, pembrolizumab, or carboplatin to women with recurrent or metastatic cervical cancer. (mskcc.org)
  • Researchers think the combination of tisotumab vedotin with bevacizumab, pembrolizumab, or carboplatin may be an effective treatment for women with cervical cancer. (mskcc.org)
  • Most or many oncologists are using carboplatin, and paclitaxel plus bevacizumab extrapolating from a Japanese study, JCOG0505, which showed significant noninferiority between the 2 platinum-based doublets. (onclive.com)
  • A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A. (cdc.gov)
  • Bristol-Myers Squibb gained Food and Drug Administration (FDA) approval for carboplatin, under the brand name Paraplatin, in March 1989. (wikipedia.org)
  • Carboplatin (NSC 241240, JM-8, CBDCA,Paraplatin) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. (selleckchem.com)
  • Calvert's formula is used to calculate the dose of carboplatin. (wikipedia.org)
  • This means that the dose of carboplatin must be adjusted for any impairment in kidney function. (wikipedia.org)
  • This carboplatin dosing calculator uses the Calvert method to calculate the total carboplatin dose needed to achieve a given AUC (area under the free carboplatin plasma concentration versus time curve) while taking into account renal function. (medscape.com)
  • The first part of the UK trial is an open label, dose-escalating, non-randomised study of reolysin given intravenously with paclitaxel and carboplatin every three weeks. (pmlive.com)
  • The primary objective of the UK trial is to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), recommended dose and dosing schedule and safety profile of reolysin when administered in combination with carboplatin and paclitaxel. (pmlive.com)
  • To determine safe dose of olaparib tablet with carboplatin. (clinicaltrials.gov)
  • Patients older than 70 years with unresectable stage III NSCLC were randomly assigned to chemoradiotherapy (60 Gy plus concurrent low-dose carboplatin [30 mg/m 2 per day, 5 days a week for 20 days]) or radiotherapy alone, using a minimisation method with biased-coin assignment balancing on Eastern Cooperative Oncology Group (ECOG) performance status (0 vs 1 vs 2), stage (IIIA vs IIIB), and institution. (thelancet.com)
  • Grover had his #3 dose of carboplatin 16 days ago before we had a weekend trip planned. (tripawds.com)
  • Based on his previous doses we check a CBC on day 9 and 14 - at his highest dose of carboplatin the WBCs started to drop on day 9 and hit the lowest on day 14. (tripawds.com)
  • We reduced his carboplatin dose after dose #1 and saw no changes on his CBC so we increased it slightly for dose #3 (but still less than dose #1). (tripawds.com)
  • Daisee's mom Michelle Fountain graciously allowed us to film their appointment, and the VCG staff allowed us to witness all of the steps involved in measuring and administering the carboplatin dose Daisee would receive. (tripawds.com)
  • The purpose of this study is to evaluate the difference in overall survival between dogs with bone cancer (osteosarcoma) treated with amputation and carboplatin, vs those treated with amputation, carboplatin, and high-dose vitamin C. (iastate.edu)
  • More than 4 years after our last case entry, we analyzed the survival results for the 44 eligible patients who received the conventional dose of carboplatin and the 43 eligible patients receiving our intensified dose of carboplatin. (elsevier.com)
  • This is a phase Ib single arm, open-label, multiple dose, dose escalating, safety, pharmacokinetic and pharmacodynamic study of the combination of PF-05212384 with paclitaxel and carboplatin. (checkorphan.org)
  • Successive cohorts of patients will receive escalating doses of PF-05212384 in combination with paclitaxel and carboplatin, starting at a dose level determined to be the 60% of single agent MTD. (checkorphan.org)
  • Isotopic measurement of renal function is warranted in patients who would otherwise have their estimated glomerular filtration rate (eGFR) and carboplatin dose capped. (medscape.com)
  • Howell SJ, Coe F, Wang X, Horsley L, Ekholm M. Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP). (medscape.com)
  • A phase I study was undertaken to identify the maximum tolerated dose (MTD) of carboplatin that could be administered with a fixed dose of doxorubicin, 60 mg/m 2 , administered every 28 days. (elsevier.com)
  • Further escalation of the carboplatin dose was then attempted, with the concomitant addition of GM-CSF 10 mg/kg per day on days 1-21. (elsevier.com)
  • At carboplatin 400 mg/m 2 and doxorubicin 60 mg/m 2 , thrombocytopenia was dose limiting. (elsevier.com)
  • At carboplatin 400 mg/m2 and doxorubicin 60 mg/m2, thrombocytopenia was dose limiting. (elsevier.com)
  • Professor Tim Oliver of Barts' Hospital has completed a large research study over the last 20 years on testicular cancer across 14 countries and concluded that one dose of carboplatin is as effective as three weeks of radiotherapy in treating testicular cancer. (canceractive.com)
  • Anatomical analysis indicated that the carboplatin alone caused relatively severe but scattered losses of inner hair cells throughout most of the cochlea which were dependent on dose and administration route. (cdc.gov)
  • The backbone regimen deviated from common practice, including the addition of carboplatin, lack of dose dense anthracyclines, and adjuvant capecitabine for residual disease, thus brining important questions regarding real-world translation of these results. (jnccn.org)
  • High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer. (nih.gov)
  • Induction therapy with carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal radiotherapy in the treatment of locally advanced, unresectable non-small cell lung cancer: preliminary report of a phase I trial. (nih.gov)
  • Understanding how to best calculate the dose of carboplatin given to patients with cancer may help doctors learn how to improve the use of carboplatin in the future. (froedtert.com)
  • Pemetrexed was administered at 500 mg/m 2 , carboplatin was given at a dose of 5 AUC, and cisplatin was administered at 75 mg/m 2 . (curetoday.com)
  • UPGRADE, the company’s Phase 1/2 umbrella trial of UpRi in combination with other agents, is currently dose escalating UpRi in combination with carboplatin. (stockhouse.com)
  • Carboplatin, Paclitaxel and Gemcitabine. (checkorphan.org)
  • 30 mL/min) and/or performance score of 2 who were randomly assigned to receive either gemcitabine/carboplatin (GC) or methotrexate/carboplatin/vinblastine (M-CAVI). (warwick.ac.uk)
  • A total of 86 patients with newly diagnosed Stage IIIB/IV SCC received up to 6 cycles of gemcitabine (1250 mg/m2) and carboplatin (AUC5) with or without Apatorsen (600 or 400 mg IV/week) until disease progression. (esmo.org)
  • Prominent & Leading Wholesale Trader from Nagpur, we offer carbokem novo 150mg injection carboplatin, vivitra trastuzumab 440 mg injection, cytogem 1000mg injection gemcitabine, neukine 300mcg injection filgrastim, trastuzumab hertraz 440mg injection and natdecita decitabine 50mg injection. (rlpharmacy.com)
  • Three patients remained on study for CARBOPLATIN has foxy liquefaction and an preprandial album profile as a potential therapeutic tool in confounding multiple target gravity from histologically computerized drug- and chemical-induced phenobarbital. (angelfire.com)
  • They have to track some of the anti-oxidant vitamins and minerals in patients with syllabic CARBOPLATIN is subtle since thankfully half of all men in the world can a scott be astrological when the UCSF researchers avian the study shows that the dietary/nutritional CARBOPLATIN may be a medical mannequin! (angelfire.com)
  • Peripheral neuropathy is uncommon when conventional doses of carboplatin are used, but patients over 65 years of age may be at higher risk. (drugs.com)
  • Carboplatin may be associated with peripheral neuropathy in about 4% to 15% of patients. (drugs.com)
  • However, in 70% of patients pretreated with cisplatin who had already developed peripheral neurotoxicity, their symptoms did not worsen with carboplatin therapy. (drugs.com)
  • The second part of the trial will immediately follow and will include the enrolment of a further 12 patients at the maximum dosage of reolysin in combination with standard dosages of paclitaxel and carboplatin. (pmlive.com)
  • Not only does this study prove that carboplatin is at least as effective as cisplatin, but it presents fewer troublesome side effects for patients. (cancernetwork.com)
  • The paclitaxel/carboplatin regimen was well tolerated by patients and caused fewer gastrointestinal, genitourinary, and metabolic effects, such as nausea, vomiting, weight loss, and kidney damage. (cancernetwork.com)
  • The study (GOG 158) randomized 808 patients to receive either carboplatin plus paclitaxel by a 3-hour infusion or cisplatin plus paclitaxel by a 24-hour infusion. (cancernetwork.com)
  • Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients. (muni.cz)
  • The aim of this study was to assess whether radiotherapy plus carboplatin results in longer survival than radiotherapy alone in elderly patients with NSCLC. (thelancet.com)
  • Adding carboplatin to neoadjuvant paclitaxel significantly improves event-free survival (EFS) in patients with triple-negative breast cancer (TNBC), but incorporating a third drug, veliparib, does not confer additional improvement, according to long-term results from the phase 3 BrighTNess trial. (empr.com)
  • The patients were randomly assigned (2:1:1) to receive paclitaxel plus carboplatin and veliparib (316 patients), paclitaxel plus carboplatin (160 patients), or paclitaxel alone (158 patients). (empr.com)
  • Determine the antitumor activity of pemetrexed disodium and cisplatin or pemetrexed disodium and carboplatin, as measured by the complete and partial tumor response rate, in patients with extensive stage small cell lung cancer. (knowcancer.com)
  • Arm II: Patients receive pemetrexed disodium as in arm I and carboplatin IV over 1 hour on day 1. (knowcancer.com)
  • The authors conducted subgroup analysis of their randomized phase II study of three different schedules of weekly paclitaxel with carboplatin to determine the efficacy of each regimen in elderly patients (aged ≥ 70 years) with advanced non-small-cell lung cancer (NSCLC). (elsevier.com)
  • METHODS: Patients with advanced NSCLC were randomized to one of three different weekly paclitaxel/carboplatin regimens. (elsevier.com)
  • CONCLUSION: The weekly regimen of paclitaxel administered in combination with carboplatin is tolerated well by elderly NSCLC patients and has comparable efficacy with younger patients. (elsevier.com)
  • To prospectively determine the incidence of carboplatin and paclitaxel hypersensitivity in these patients undergoing retreatment with both agents as first recurrence therapy. (checkorphan.org)
  • Eligible patients were randomly assigned (2:1)using a permuted block method (block size of six patients)to receive six cycles of paclitaxel (175 mg/m 2 )and carboplatin (area under the serum concentration-time curve 5 or 6)every 3 weeks, plus weekly intravenous trebananib 15 mg/kg or placebo. (elsevier.com)
  • Objective This study aimed to evaluate the efficacy of paclitaxel and carboplatin in patients with completely or optimally resected uterine carcinosarcoma. (bmj.com)
  • Patients received 6 courses of 175 mg/m 2 paclitaxel over 3 hours, followed by a 30-minute intravenous administration of carboplatin at an area under the serum concentration-time curve of 6. (bmj.com)
  • Conclusions The combination of paclitaxel and carboplatin was a feasible and effective postoperative adjuvant therapy for patients with completely or optimally resected uterine carcinosarcoma. (bmj.com)
  • Of the 6 patients treated with carboplatin 400 mg/m 2 , doxorubicin 60 mg/m 2 , and GM-CSF, grade 4 granulocytopenia and thrombocytopenia were seen in 4 and 5 patients, respectively. (elsevier.com)
  • Purpose: To evaluate the efficacy of the carboplatin/paclitaxel combination in patients with carcinoma of unknown primary site (CUP). (ucy.ac.cy)
  • There was no pharmacokinetic difference in the patients' handling of ultrafilterable platinum therefore it is possible that there is an intrinsic rhythm of susceptibility of bone marrow to carboplatin. (ox.ac.uk)
  • Patients on carboplatin were also less lethargic and returned to work earlier. (canceractive.com)
  • All patients were given paclitaxel (200 mg/m2 ) and carboplatin (AUC 6) on day 1, every 21 days and celecoxib (400 mg) daily. (tanaffosjournal.ir)
  • Aim: In this study we determined the protective role of amifostine against the side effects of the combination of paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). (uludag.edu.tr)
  • A multiinstitutional phase II clinical trial was conducted to evaluate the activity and toxicity of paclitaxel, carboplatin, and concurrent radiation therapy on patients with locally advanced NSCLC. (elsevier.com)
  • After chemoradiation therapy, patients received an additional two cycles of paclitaxel 200 mg/m 2 over 3 hours and carboplatin at AUC 6 every 3 weeks. (elsevier.com)
  • This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. (ucsf.edu)
  • It is not yet known whether giving letrozole alone or in combination with paclitaxel and carboplatin works better in treating patients with low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum compared to paclitaxel and carboplatin without letrozole. (ucsf.edu)
  • ARM I: Patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. (ucsf.edu)
  • In the four-arm clinical trial, 559 patients with untreated, metastatic, squamous NSCLC all received carboplatin plus either paclitaxel or nanoparticle albumin-bound (nab)-paclitaxel ( Abraxane, Celgene) for the first four cycles. (medscape.com)
  • Methods: Patients with previously untreated advanced nonsquamous NSCLC without sensitizing EGFR or ALK alterations were randomly assigned 1:1 to receive open-label pemetrexed 500 mg/m 2 plus carboplatin at area under the concentration-time curve of 5 mg/mL/min (four cycles) with or without pembrolizumab 200 mg (up to 2 years), with optional pemetrexed maintenance, each administered every 3 weeks. (elsevier.com)
  • Patients and Methods: Untreated stage IIIB/IV patients with PS 0/1 were randomly assigned (1:1) to carboplatin AUC6, day 1 every 3 weeks, and either nab-paclitaxel (Abraxane) 100 mg/m 2 weekly (nab-P/C) or solvent-based paclitaxel (Taxol) 200 mg/m 2 day 1 every 3 weeks (sb-P/C). The primary end-point was overall response rate (ORR). (elsevier.com)
  • However, both the Japanese and international guidelines recommend a three-drug combination of a neurokinin 1 receptor antagonist (NK1RA), a 5HT3RA, and dexamethasone for patients receiving carboplatin, which is classified as MEC. (researchsquare.com)
  • However, whether the addition of an NK1RA to a 5HT3RA and steroid combination is beneficial in patients receiving MECs other than carboplatin-based regimens remains controversial. (researchsquare.com)
  • Avastin, in combination with carboplatin and paclitaxel, is indicated for the first‑line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer. (avastin.com)
  • 80 percent of the patients respond to the treatment that involves taxol and carboplatin. (hstalks.com)
  • Taxol, Seattle-based ancestry vista hemolytic in a research study chile two therapies: a drug nonviolent xr7 or tympanum on that line CARBOPLATIN has one paresis drug on the neck, and, if so, what were the breathed doses of birmingham to coalesce harming operculated tissues, acquainted to Roach. (angelfire.com)
  • I have had 4 treatments of IPI followed by 6 weeks of radiation followed by 15 taxol/ carboplatin treatments. (melanoma.org)
  • The model found the sequence of carboplatin, capecitabine, eribulin resulted in the lowest cost and higher QALYs. (oncologynurseadvisor.com)
  • Carboplatin injection comes as a solution (liquid) to be injected over at least 15 minutes intravenously (into a vein) by a doctor or nurse in a medical facility. (medlineplus.gov)
  • tell your doctor and pharmacist if you are allergic to carboplatin, cisplatin (Platinol), any other medications, or any of the ingredients in carboplatin injection. (medlineplus.gov)
  • Carboplatin 450 mg Injection is an anticancer drug and is classified as an alkylating agent. (cancerdrugs.co.in)
  • The name of our company surfaces prominently among the trusted Suppliers and Exporters of Carboplatin 450 mg Injection from Maharashtra, India. (cancerdrugs.co.in)
  • If Carboplatin 450 mg Injection has been approved for one use, physicians may elect to use this same in jection for other problems if they believe it may help. (cancerdrugs.co.in)
  • Taj Pharmaceuticals is reputed manufacturer and Carboplatin Injection BP 50mg/5ml suppliers in India prefer Taj Pharmaceuticals due to the reliability and purity of products. (tajgenerics.com)
  • best quality supplier and exporter of Carboplatin Injection BP Taj Pharmaceuticals manufactures a wide range of pharmaceuticals formulation involving Tablets / Capsules / Injections and Orals. (tajgenerics.com)
  • Taj Pharma India teamhas an excellent expertise in manufacturing and export of Carboplatin Injection BP. (tajgenerics.com)
  • Taj Pharmaceuticals has performed these business activities related to exports of Carboplatin Injection BP for major foreign-affiliated pharmaceutical import companies, ministry of health, tenders etc. and have enjoyed the full confidence of these companies, instructions and governments. (tajgenerics.com)
  • Taj Pharmaceuticals is manufactures Carboplatin Injection BP 50mg/5mlunder WHO-cGMP Plant. (tajgenerics.com)
  • Taj Pharma is licenced to manufacture Carboplatin Injection BP 50mg/5mlformulation from Food and Drug Administration of Indian authorities as the rules and regulations with all compliances for international markets. (tajgenerics.com)
  • In terms of its structure, carboplatin differs from cisplatin in that it has a bidentate dicarboxylate (the ligand is CycloButane DiCarboxylic Acid, CBDCA) in place of the two chloride ligands, which are the leaving groups in cisplatin. (wikipedia.org)
  • For this reason, "CBDCA" is sometimes used in the medical literature as an abbreviation referring to carboplatin. (wikipedia.org)
  • Carboplatin (CBDCA) is a second-generation cisplatin analog that has shown activity in early clinical trials. (elsevier.com)
  • He noted that the addition of carboplatin to a standard neoadjuvant regimen "clearly" showed evidence of an increase in pCR. (medscape.com)
  • The cell cycle progression of U-373MG cells was affected by the addition of carboplatin, while the amount of mutant p53 also increased in their nuclei. (elsevier.com)
  • Carboplatin exhibits lower reactivity and slower DNA binding kinetics, although it forms the same reaction products in vitro at equivalent doses with cisplatin. (wikipedia.org)
  • If carboplatin is combined with other neurotoxic cancer treatments, or used at higher doses or for prolonged periods, the risk of more severe neuropathy may increase. (drugs.com)
  • Group 1: Participants will receive olaparib tablets twice a day for 7 days (14 doses) and will receive carboplatin by vein on day 1 or 2, for a 21-day treatment cycle. (clinicaltrials.gov)
  • Group 2A: Participants will receive olaparib tablets twice a day for 7 days (14 doses) and then carboplatin on day 8 of the first cycle. (clinicaltrials.gov)
  • Cycle 2 will start with carboplatin on day 1 and olaparib starting on day 2 for 7 days (14 doses). (clinicaltrials.gov)
  • Cycle 2 will start with 7 days of olaparib (14 doses) and carboplatin will be given on day 8. (clinicaltrials.gov)
  • They said consistent guidelines on calculating carboplatin doses are warranted. (medscape.com)
  • In all, 60 courses of therapy were delivered, all with doxorubicin and with carboplatin doses of 250 mg/m 2 , 325 mg/m 2 and 400 mg/m 2 . (elsevier.com)
  • Carboplatin is usually given by infusion into a vein (intravenous, IV). (cancerdrugs.co.in)
  • PRIMARY OBJECTIVE: I. To examine if letrozole monotherapy/maintenance (L/L) is non-inferior to intravenous (IV) paclitaxel/carboplatin and maintenance letrozole (CT/L) with respect to progression-free survival (PFS) in women with stage II-IV primary low-grade serous carcinoma of the ovary or peritoneum after primary surgical cytoreduction. (ucsf.edu)
  • This has led to carboplatin based adjuvant therapy being generally preferred over adjuvant radiotherapy in clinical practice. (wikipedia.org)
  • two were considered to be related to paclitaxel and carboplatin (general physical health deterioration and platelet count decreased). (elsevier.com)
  • Background: Both paclitaxel ( P) and carboplatin ( C) have significant activity in non-small cell lung cancer (NSCLC). (ksbu.edu.tr)
  • Non-small cell lung cancer (NSCLC) is the most common cause of cancer-related deaths worldwide and is primarily treated with radiation, surgery, and platinum-based drugs like cisplatin and carboplatin. (mpg.de)
  • Conclusion: Combined modality therapy with paclitaxel, carboplatin, and radiation is a promising treatment for locally advanced NSCLC that has a high response rate and acceptable toxicity and survival rates. (elsevier.com)
  • Methods: To better understand outcomes in these patient populations, we performed a pooled analysis using data from the ABOUND clinical trial program (ABOUND.SQM, ABOUND.PS2, ABOUND.70+) and the key phase III trial of nab-paclitaxel/carboplatin in advanced NSCLC. (wustl.edu)
  • Conclusion: Based on this study, adding 400 mg celecoxib to the standard regimen (paclitaxel plus carboplatin) does not enhance time to progression and overall survival compared to historical data. (tanaffosjournal.ir)
  • Dr Loibl noted that the higher rates of hematologic adverse events in the carboplatin-containing arms, which were previously reported, 2 did not compromise treatment delivery or efficacy. (empr.com)
  • Thus, we designed a phase II trial to evaluate the efficacy of the combination of paclitaxel, carboplatin and celecoxib in advanced non-small cell lung cancer. (tanaffosjournal.ir)
  • Starting on the left side of a drug name, TML highlights the differences between similar drug names by capitalizing dissimilar letters (e.g., vinBLAStine versus vinCRIStine and CISplatin versus CARBOplatin). (fda.gov)
  • Your doctor will order certain tests before, during, and after your treatment to check your body's response to carboplatin. (medlineplus.gov)
  • Carboplatin is used alone or in combination with other medications to treat cancer of the ovaries (cancer that begins in the female reproductive organs where eggs are formed) that has spread to other parts of the body, not improved, or that has worsened after treatment with other medications or radiation therapy. (medlineplus.gov)
  • The nadir of this myelosuppression usually occurs 21-28 days after the first treatment, after which the blood cell and platelet levels in the blood begin to stabilize, often coming close to its pre-carboplatin levels. (wikipedia.org)
  • This is not all the information you need to know about carboplatin for safe and effective use and does not take the place of talking to your doctor about your treatment. (drugs.com)
  • To determine the safety and effectiveness of combined carboplatin and olaparib as a treatment for gynecologic (female organ) or breast cancer. (clinicaltrials.gov)
  • All participants may receive no more than 8 cycles of olaparib and carboplatin therapy, but may continue to take olaparib if their cancer responds to the treatment. (clinicaltrials.gov)
  • The overall survival (OS) was not significantly different across the 3 treatment arms, but there was a trend toward superiority in the carboplatin-containing arms. (empr.com)
  • The study, published in Breast Cancer Research and Treatment, retrospectively examined the effect of local carboplatin guidelines on pathological complete response (pCR) and toxicity in women with HER2+ breast cancer receiving neoadjuvant docetaxel , carboplatin, trastuzumab and pertuzumab (TCHP). (medscape.com)
  • Combination therapy with WNT974 and carboplatin resulted in a higher percentage of samples that showed ≥30% reduction in ATP concentration than either single drug treatment. (nature.com)
  • The combination of WNT974 and carboplatin induces cytotoxicity plus cell cycle arrest in a higher percentage of ascites samples than with single drug treatment. (nature.com)
  • Carboplatin treatment at 06.00 is associated with significantly greater thrombocytopenia than at 18.00 (platelet nadir 95,000 versus 180,000, p less than 0.05). (ox.ac.uk)
  • Evoked-potential thresholds and cubic distortion product otoacoustic emissions in the chinchilla following carboplatin treatment and noise exposure. (cdc.gov)
  • We've had a lot of changes over the last 5 years in terms of treatment, but to a certain extent, sort of the gold standard I think remains the same, which is this is a carboplatin/paclitaxel doublet. (pharmacytimes.com)
  • Our phase III results showed TECENTRIQ in combination with Avastin, paclitaxel and carboplatin has the potential to provide a significant survival benefit in the initial treatment of metastatic non-squamous non-small cell lung cancer," said Sandra Horning, MD, Roche's Chief Medical Officer and Head of Global Product Development. (worldpharmanews.com)
  • Carboplatin or Cisplatin remains the backbone of treatment. (delveinsight.com)
  • In the primary analysis, paclitaxel plus carboplatin, with or without veliparib, improved the rate of pathological complete response (pCR) when compared with paclitaxel alone. (empr.com)
  • This analysis led to the identification of a promoter CpG island methylation of LDL receptor-related protein 12 (LRP12) associated with increased resistance to carboplatin. (mpg.de)
  • Some results show that cisplatin and carboplatin cause different morphological changes in MCF-7 cell lines while exerting their cytotoxic behaviour. (wikipedia.org)
  • He explained that carboplatin improved the pCR rate, but it is not known if that will result in significant improvement in recurrence-free or overall survival. (medscape.com)
  • There was no significant difference in event-free survival between the carboplatin-containing arms. (empr.com)
  • Fedelty Health Care is a certified Carboplatin Bulk Pharma Exporter , Cargo Bulk Supplier, and pharmaceutical wholesaler in India. (fedeltyhealthcare.com)
  • In researching the platinum drugs it appears to me that carboplatin is easier to handle than cisplatin and similar in effectiveness. (lungevity.org)
  • Usually, the combination includes a platinum compound (usually cisplatin or carboplatin), and a taxane, (such as paclitaxel or docetaxel). (biocon.com)
  • Carboplatin has also been used for adjuvant therapy of stage 1 seminomatous testicular cancer. (wikipedia.org)
  • Other neurologic complications of carboplatin therapy may include retinal (eye) toxicity that may lead to vision loss and ototoxicity that may lead to hearing loss or ringing in the ears (tinnitus), although these side effects tend to be more common with cisplatin. (drugs.com)
  • From cycle 3 until completion of therapy, all Group 2 participants will follow the schedule used for Group 1 (carboplatin on day 1 or 2 of the week of olaparib therapy, also in 21-day cycles). (clinicaltrials.gov)
  • The severity of thrombocytopenia was related to the calculated carboplatin AUC and also to baseline platelet count and prior therapy. (elsevier.com)
  • We identified a set of 40 candidate regions with methylation correlated to carboplatin response and corresponding inverse gene expression pattern even before therapy. (mpg.de)
  • Phase II Trial of Celecoxib in Combination with Paclitaxel and Carboplatin in Advanced Non-Small Cell Lung Cancer', TANAFFOS (Respiration) , 6(1(winter)), pp. 37-46. (tanaffosjournal.ir)
  • Compared with paclitaxel plus carboplatin, the HR for EFS was 1.12 for paclitaxel plus carboplatin and veliparib (95% CI, 0.72-1.72, P =.62). (empr.com)
  • 1.25 for paclitaxel plus carboplatin and veliparib vs paclitaxel and carboplatin (95% CI, 0.70-2.24, P =.46). (empr.com)
  • Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. (iu.edu)
  • SAN ANTONIO - Adding carboplatin to paclitaxel in the neoadjuvant setting for triple-negative breast cancer significantly improves pathologic complete response (pCR) rates. (medscape.com)
  • None of the samples submitted for carboplatin and vinblastine were positive. (cdc.gov)
  • MATERIAL AND METHOD: The medical records and electrocardiographic data of women with EOC who received paclitaxel (175 mg/min2) and carboplatin (AUC=5) every 3 weeks at Chiang Mai University Hospital between January 2000 and December 2004 were reviewed for cardiac risk factors and clinical consequence. (who.int)
  • In this study, you will inhabit two flowchart (heat) and carboplatin treatments then be re-evaluated to extend if you are responding to louisville. (angelfire.com)
  • Craig vanuatu of Medicine and nosiness of Medical sufferer at dichloromethane larder Medical Center, and the facts diligently ovulate that the rugged drug, CARBOPLATIN was frozen for head and neck toluene. (angelfire.com)
  • Carboplatin is a platinum-based antineoplastic drug that damages DNA by forming intrastrand cross-links with neighboring guanine residues. (sigmaaldrich.com)
  • There were concerns that carboplatin would be less effective when compared to cisplatin, the drug that had been previously used with paclitaxel, said Robert F. Ozols, MD, PhD, senior vice president of Medical Science at Fox Chase Cancer Center in Philadelphia. (cancernetwork.com)